2023 BeiGene

Responsible
Business &Sustainability
REPORTTable ofContents

A Letter from Leadership  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 3

Innovating Sustainably  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 39

Our Mission, Vision & Values  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 42023 Goals & Progress .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 40
Our Climate Governance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 41
Our Climate Strategy  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 42

Our Approach to Responsible
Business & Sustainability .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 5

Our Climate Risk Management .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 45

Guiding Principles .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 6

Our Climate Metrics  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 46

Strategy & Process  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 72023 Goals & Progress  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 9

Operating Responsibly  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 49
Corporate Governance  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 50

Advancing Global Health  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 13

Enterprise Risk Management  . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 53

Our Approach to Innovation & Clinical Development  .  . 15

Our Policies  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 54

Pursuing Broad Access to Our Medicines  .  .  .  .  .  .  .  .  . 20

Product Quality Control Systems  .  .  .  .  .  .  .  .  .  .  .  .  .  . 56

Advancing Global Health Equity .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 22

Responsible Procurement  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 59

BeiGene Foundation  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 23
Supporting Patients  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 25

Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
GRI & HKEX Index  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 62

Empowering Our Colleagues . .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 27

SASB Index  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 74

Building Our Team . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 28

Task Force on Climate-Related Financial Disclosures .  . 76

Colleague Engagement & Support  .  .  .  .  .  .  .  .  .  .  .  .  . 29
Compensation & Benefits  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 31
Career Development  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 33

About This Report .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 77
Forward-Looking Statement .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 78

A Culture of Belonging  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 35
Employee Volunteerism  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 37
Health & Safety  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 38

Next:
A Letter from Leadership

Introduction

A Letter from
Leadership
Together with our colleagues, we are pleased
to share this year’s Responsible Business &Sustainability Report.
In 2023, BeiGene experienced tremendous growthboth internally and with our stakeholders around theglobe. Firmly rooted in our Responsible Business& Sustainability focus areas and priorities, weachieved several key initiatives. These include thedevelopment of our global health equity strategy;
the approval of our first Scope 1 and Scope 2
quantitative emissions-reduction goal; the evolutionof our diversity, equity, inclusion, and belonging(DEI&B) strategy; the elevation of patient insights inour drug development strategy; and the launch of
the BeiGene Foundation.
Embodying our value of Bold Ingenuity, our prolificinternal discovery engine powered us to over 20
candidates in our clinical pipeline. Additionally, we
regained global rights to TEVIMBRA® (tislelizumab),one of our cornerstone, internally developed
medicines, and BRUKINSA® (zanubrutinib) received
a steady stream of regulatory approvals. This
year, we achieved the remarkable milestone of

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

BRUKINSA and TEVIMBRA treating more than one

business while cultivating positive change in society

million patients around the world.

includes how we engage with the communities

Innovating
Sustainably

OperatingResponsibly

Appendixpractices to become a more resilient organization.

in which we work and live. In 2023, we launched

We thank our stakeholders for their support andTo continue delivering on our mission to bring thethe BeiGene Foundation as an independent 501(c)commitment to our mission and growth. Our

highest-quality therapies to more patients and(3) organization to provide grants to charitableachievements over the past year are a testament tofurther affirm our value of Patients First, we alsoorganizations aligned with the Foundation’s mission

their passion and dedication to improving the lives

developed a comprehensive Global Health Equity

to eliminating barriers to equitable and accessibleof people across the world. As we look ahead, weStrategy in 2023. In its inaugural year, the Global

cancer care in underrepresented communities

anticipate numerous opportunities to expand our

Human Equity Working Group laid the foundation

around the world. The first grant made by theclinical reach, improve our commitment to operating

for BeiGene to be a leader in health equity and

BeiGene Foundation was to The Max Foundation as

responsibly, and further our sustainability goals.

DEI&B in the years to come. The working grouppart of a partnership with BeiGene to provide accessestablished a governance structure, defining a vision

to BRUKINSA to patients in low- and middle-income

We invite you to explore this report to learn more

and mission for our strategy that reflect the voices

countries.

about our Responsible Business & Sustainability

and needs of patients, communities, and colleagues,

commitments and our ongoing mission as a good

and articulated where BeiGene will focus its global

Finally, our value of Driving Excellence encompasses

health equity efforts.

our continued focus in 2023 on decreasing ourcorporate citizen and leading oncology innovator.

environmental impacts and combatting climate
Our advancements in bringing life-saving

change. This year, our Responsible Business &medicines to patients around the world are thanks

Sustainability Working Group approved our Scope 1

to more than 10,000 colleagues across fiveand Scope 2 goal to reduce emissions by 25%

continents. In 2023, our rapid growth and ability

per unit of internally manufactured commercial

to attract talent resulted in an increase of 2,625

product by 2026. We also completed a Scope 3

new colleagues to our diverse and global team.

global footprint analysis and moved ahead withWe also furthered our value of Collaborative Spirit

plans to launch a supplier engagement program,and strategic focus on a culture of belonging

which together will lay the groundwork to establish athrough the introduction of our Core Competencies,

Scope 3 reduction goal by 2025. In addition, findings

enhanced mental health and well-being benefits,

from our climate risk assessment were integrated

and a revamped DEI&B strategy designed to evolve

into our enterprise risk management process.

BeiGene into a diversity-mature organization.

This integration will allow these considerations toCreating a culture that embraces responsible

inform our strategy for adapting our operations and3 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTJohn V. Oyler
Chairman of theBoard of Directors,
Co-Founder and CEO

Ranjeev Krishana
Lead Independent Director,
Board of Directors

Introduction

Our Mission,
Vision & Values

AdvancingGlobal Health

Our Approach

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

BeiGene by the Numbers

Mission
Build a next-generation global oncology company—one that expands the highest-quality therapies
to people around the world—through courage, persistent innovation, and challenging the status quo.

$2.5 billion$3.2 billion

10,000+20+

65+

22,000+in annual product revenue

Visioncash balance

Transform the biotechnology industry, creating impactful medicines that will be accessible to far
more cancer patients around the world.

ValuesPatients First. Stand up for more affordable medicinescolleagues on 5 continents

clinical candidates in pipeline

for patients everywhere, and improve global healthand well-being
Bold Ingenuity. Challenge the status quo to deliverscience once thought to be impossible, and makebold commitments and deliver against them
Collaborative Spirit. Foster superior,
non-hierarchical teamwork, and respectindividual differences
Driving Excellence. Make a lasting impact in the world,countries withregulatory approvals

patients1 enrolled in clinical
trials with BeiGene assets to date

1M+

20,000+Over one million patients treated with
BRUKINSA and TEVIMBRA to dateand have a sense of urgency and agility to follow thescience and deliver for patients while maintaining integrity
1

4 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Number of patients includes those in Investigator Initiated Trials (IITs)

volunteer hours logged bycolleagues globally

Introduction

Our Approach

AdvancingGlobal Health

Our Approach to

Responsible
Business& Sustainability
Responsible Business & Sustainability (RB&S) is at the core

In this chapter,of everything we do. We are guided by our commitment to

we share our approach to being a leading corporate citizen

challenging the status quo, removing systematic injustices andon behalf of all our stakeholders. This includes our:inequities, and transcending borders to transform healthcare
access. We recognize that to execute our mission, we must

Guiding Principles

operate in an ethical and responsible manner, investing in

Strategy & Process

operational efficiencies and minimizing risk wherever possible2023 Goals & Progressto ensure long-term sustainable growth.

5 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Guiding Principles

BeiGene recognizes that all 17 of the SDGs are

To guide our approach to operating responsibly andessential to sustainable development, we haveachieve our commitment to positively impact theprioritized three goals that our business structure

lives of our patients and society, we have aligned

is best positioned to meaningfully impact andour strategy and goals with international frameworks

advance:Our Approachthat advance commitments to a prosperous, just,and sustainable planet.

GOAL
Develop a strategy to align with the United
Nations Global Compact’s guidance onhuman rights by 2025

We have taken SDGs 3, 5, and 13 into account as
we map our strategic goals for 2030 and beyond
and have committed to reporting annually to the
UNGC on our progress. As part of this commitment,

United Nations Global Compact &Sustainable Development Goals
The United Nations Global Compact (UNGC) is a
strategic initiative that supports organizations as theyalign their operations and strategies with universal
principles regarding human rights, environmental
protection, and labor standards. To further ourcommitment to these goals, BeiGene has been asignatory of the UNGC since 2022.
Since joining the UNGC, we have also worked
to align our initiatives with the UN’s Sustainable
Development Goals (SDGs), which serve as the

BeiGene has also stated our intention to align ourpolicies and work with the UNGC’s standards forhuman rights. While BeiGene already works tomeet all regional and international laws regarding
human rights, as a global organization we havea responsibility to do more to ensure that humanrights are recognized and respected throughout theworld. This commitment will also help safeguard
BeiGene’s policies to ensure they are effectively
carried out.
To learn more about progress on our goals,
see 2023 Goals & Progress, page 9.

international community’s blueprint to develop asafe and equitable world for all. With deadlines set
for 2030, the SDGs represent a multiyear strategy
to impact business awareness and action. While

6 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Strategy & Process

Empowering
Our Colleagues

strategy is defined by our strategic framework and

HIGH

to expand and accelerate access to the highestquality therapies for patients around the world.

•

Our Material Topics
assessment, we interviewed key members

stakeholders. This process enabled us to identify
and rank the topics most relevant to our operations
and performance.
The results reinforced our commitment to bringing
innovative medicines to more patients globally andRelevance to stakeholders

relevant nonprofit organizations, and other external

•

•
•
•

of providing a work environment that promotes
employee well-being and belonging; reducing our

These themes became the foundation for our four

7 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTDiversity, Equity, Inclusion, and Belonging
Bioethics•••

Government Relations

Employee Volunteerism

Charitable Donations

Waste Management

communities; and practicing good governance.

Operating Responsibly.

Responsible Marketing

Other Air Emissions

environmental impact; supporting patients and local

Our Colleagues, Innovating Sustainably, andIntellectual Property Protection

Employee Engagement

Employee Benefits

to our stakeholders. Along with advancing global

focus areas: Advancing Global Health, Empowering

•
•
•
•

Product Innovation
Access to Products
Product Affordability
Clinical Practices

Employee Development
Water Use

Supply Chain Management

demonstrated the significance of this imperative
health, the assessment highlighted the importance

••
••
•

• •
•
•
• •
•
•

Data Privacy

Employee
Healthand Safetyof BeiGene’s leadership team, conducted an
the investor community, industry organizations,OperatingResponsibly

Product Quality
Product Safety
Business Ethics
Patient Outcomes

ClimateChange andEnergy Use

To complete our most recent materiality

employee survey, and reviewed expectations from

Innovating
Sustainably

BeiGeneMateriality Assessment
BeiGene Materiality Assessment

BeiGene’s Responsible Business & Sustainability
material topics and is firmly rooted in our commitment

AdvancingGlobal Health

Our Approach

LOW

Signiﬁcance of economic, environmental, and social impacts

HIGH

AppendixIntroduction

Our Responsible Business & Sustainability Strategy
In 2021, BeiGene launched our Responsible Business & Sustainability strategy. The
strategy has four focus areas, Advancing Global Health, Empowering Our Colleagues,
Innovating Sustainably and Operating Responsibly, each with defined strategic
priorities and goals. In 2023, we made progress toward, and achieved several goals,
including the approval of our first Scope 1 and Scope 2 quantitative emissions
reduction goal, the launch of the BeiGene Foundation, and the development of a
global health equity framework. As previously stated, these goals are intentionallyaligned with the UN SDGs: Good Health and Well-Being (SDG 3), Gender Equality(SDG 5), and Climate Action (SDG 13).

8 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTOur Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix2023 Goals & Progress
Each year, BeiGene reviews our efforts toward achieving our strategic priorities.
In 2023, we made substantial progress across all four focus areas. A summary of our progress is below.

Focus Area

2023 Goal

U.N. Sustainable
Development Goal (SDG)

2023 Progress

Advancing Global Health

Product Innovation

10 molecules in clinic between 2022 and 2023

AccessContinue to seek approvals for our medicines globally

3 molecules entered the clinic in 2022 and 5 molecules entered the clinic in 2023

Our medicines are approved in 65+ countries and regions
38 marketing authorization applications in multiple indications under review around the worldPartnered with patient organizations to gain patient insights in our clinical studies
Patient Engagement

Spearhead multi-stakeholder solutions that empower patients and disrupt
systemic access barriers by 2025

Charitable Giving

Establish and launch the BeiGene Foundation

9 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Finalization of the Patient Engagement Guidebook to provide a robust roadmap on where, why,
and how best to include patient insights into the pipeline at all stages of drug development

Launched the BeiGene Foundation, a 501(c)(3) organization, and subsequently
donated its first grant to the Max Foundation

Introduction

Focus Area

Goal

Our Approach

AdvancingGlobal Health

U.N. Sustainable Development
Goal (SDG)

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix2023 ProgressEmpowering Our Colleagues

DEI&B

Global gender parity at the VP level and above by 2030

38% of positions at the VP level and above are held by women

50% improvement in workforce diversity (underrepresented groups)
company-wide at management levels in the U.S. by 2030

Workforce diversity at management levels in the U.S. stayed consistent in 2023

Continue to address the composition of the Board of Directors
for gender and U.S. underrepresented groups

Efforts to improve Board diversity are ongoing

Maintain colleague engagement scores globally versus 2022 engagementscores with a stretch goal of +3% for the 2024 engagement survey

We plan to conduct an engagement survey in 2024 to track
our progress against 2022 benchmarks

Improve work-life balance survey scores by 3%, with a stretch goal of 5% in 2023

Work-life balance survey score was maintained but did not increase

Engage colleagues by 10,000 hours of global volunteerism by 2023

BeiGene colleagues engaged in over 20,000 hours of volunteer service globally

Expand volunteer paid time-off policy

Volunteer paid time-off policy was expanded to include all global colleagues

Colleague
Engagement

Volunteerism

10 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Focus Area

Our Approach

Goal

AdvancingGlobal Health

U.N. Sustainable Development
Goal (SDG)

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

2023 Progress

Innovating Sustainably

Set a quantitative Scopes 1 and 2 emissions goal by 2024

Scope 1 and Scope 2 quantitative emissions reduction goal established

Climate Change
Set a quantitative Scope 3 emissions goal by 2025. To advance this goal,
engage with top suppliers most likely to contribute to Scope 3 emissions*

Product StewardshipCompleted Scope 3 global footprint analysis for 2022 and 2023
Laid groundwork for activating top supplier engagement program in 2024

Develop a global product stewardship program

Continued development of internal product stewardship strategy to understandand mitigate the upstream and downstream impacts of our products

Implement a third-party supplier risk management program in 2023

Third-party supplier management program formally launched

Operating Responsibly

Responsible Sourcing*This goal was adjusted from the 2022 report to better align with our focus to engage with strategic suppliers that will have the most meaningful impact on our longer term emissions reduction efforts.

11 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTAppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

New Goals
Based on our progress in 2023, BeiGene has set several new goals aligned with our material issues.
A summary of our new goals are below.

Focus Area

2023 Goal

Product Innovation

Bring multiple high quality new molecules from discovery into the clinic on an annual basis*

Volunteerism

Engage colleagues in 10,000 hours of global volunteerism in 2024, with a stretch goal of 20,000 hours

Climate Change

Reduce our Scope 1 and 2 emissions by 25% per unit for our internally manufactured
commercial product by 2026 (with 2021 as a base year)

Human Rights

Develop a strategy to align with the United Nations Global Compact’s guidance on human rights by 2025

Data Privacy

Develop a plan to better align key privacy performance metrics with RB&S practices by 2025

*This goal was adjusted from the 2022 Report to better align with our focus on advancing only the most high-quality molecules into the clinic.

12 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

U.N. Sustainable
Development Goal (SDG)

AppendixIntroduction

Our Approach

AdvancingGlobal HealthWe fundamentally believe that all patients deserve accessto high-quality, innovative, and impactful medicines. Cancer
has no borders, and so, as a global company, we seek toensure our therapies are widely and easily available. From
the discovery of life-changing therapies to our efforts to close
existing health equity gaps, our vision is to confront cancer
by creating impactful medicines that will be affordable andaccessible to patients around the world.

In this chapter,
we outline how wedeliver on this through:Our Approach to Innovation &Clinical Development
Pursuing Broad Access to Our Medicines
Advancing Global Health Equity

Putting Patients First means more than providing medicine;

BeiGene Foundation

we also seek to support our patients’ families, caregivers, andSupporting Patientsthe advocacy organizations that act on their behalf. We arededicated to elevating patient voices, improving their support
structures, and evolving the global health conversation to
improve patient care.

13 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

A Differentiated Approach
Our mission is to build a next-generation global oncology company—one that extends thehighest-quality therapies to more people around the world—with passion, persistence,and excellence. With one of the largest oncology research organizations in the industry,
our entrepreneurial team is steadfast in its commitment to discovering and developing
innovative medicines that help the world’s cancer patients get the medicines they need.
To do so, we have developed a differentiated approach:We vertically integrated our clinical development process to enable better control
over quality, speed, and costs, as well as higher levels of engagement with site
investigators in BeiGene-sponsored clinical trials. We also seek
to continually expand the reach of our clinical trials to accelerate regulatory
approvals in more countries.



We apply a commercial strategy that brings innovative, high-quality therapies to
the greatest number of patients as quickly as possible. We
actively seek to build collaborations with health systems to accelerate theavailability of our medicines to patients around the world.



Coupled with our approach to improving access, we are exploring ways toincorporate principles of health equity across BeiGene, including in the designof clinical trials, our engagement with patients, and the support we offer
communities through strategic partnerships.

14 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTAppendixIntroduction

Our Approach toInnovation & ClinicalDevelopment

Our Approach

Cutting-Edge Research

20+

candidates are being evaluated inclinical development, 16 of which wereinternally developedwith cancer each year, and that figure is expected
to rise by over 10 million by 2040 . Addressing thisOperatingResponsibly

Appendix

have more than 20 potential medicines in our clinicaldiscovery into the clinic, pursuing our strategy toevaluate first-in-class and best-in-class candidates
in early clinical development and advance themost promising ones into later-stage trials. We also
recognize the importance of external collaboration
to help us advance innovation, and thus seek to

2,3

As we continue to expand our research andpartner with the best minds in academia, biotech,development (R&D) and clinical development

and pharma around the world.

Our team of dedicated scientists in biology,

efforts, we are resolute in our pursuit of pioneeringchemistry, pharmacology, translational medicine, andtherapies and novel combinations in the areas ofclinical science are motivated by the challenges ofgreatest impact. To achieve this, we actively seek

creating tomorrow’s medicines. Our ability to deliver

new methods and technologies that extend ourinnovative, life-saving therapies stems from our value

reach into potentially large indications and diversify

of Bold Ingenuity. We currently have over 20 clinical

our innovation platforms. Our pursuits include:

GOAL
Enter 10 molecules into clinic
between 2022 and 2023

candidates in development, including four in-licensed• 3 molecules entered clinic in 2022
and 5 molecules entered clinic in 2023,
for a total of 8 molecules in clinic

Employing translational innovation by bringing
together cross-disciplinary teams to advanceof the world’s cancers by incidence.

novel therapies to meet unmet patient needs
BeiGene’s oncology-focused research team, with

Innovating
Sustainably

bringing multiple high-quality new molecules from20 million people around the world are diagnosed

assets. Further, our research and therapies cover 80%

Empowering
Our Colleagues

pipeline. We are continuing to grow strategically by

The global challenge of cancer is expansive—almost

critical challenge requires novel innovation.

AdvancingGlobal HealthLeveraging technologies like chimeric• Bring multiple high-quality new
molecules from discovery into theclinic on an annual basis4

Advancing Solid Tumor
Breakthroughs with
Strategic Partners
In July 2023, BeiGene and DualityBio

more than 1,100 scientists, is one of the largest in

degradation activating compounds (CDAC),

the industry and continually seeks to accelerate thebispecific and trispecific antibodies (BsAb/TsAb),

rate at which we discover innovative medicines for

antibody-drug conjugates (ADC), cell therapy,

an innovative vision for cancer therapy: theand messenger ribonucleic acid (mRNA) therapy

delivery of highly potent anti-cancer agents

Applying learnings from our broad coverage

to tumor cells with minimal damage tothan 2,600 colleagues, is fueling this innovationin oncology to explore other types of cancers

normal cells5. As BeiGene continues to growthrough its passion and commitment to developing

including head and neck, lung, breast, upper GI,

new therapies. With our unique business model, weand colorectal

patients with the highest unmet needs. Additionally,
our global clinical development team, with moredraw from the best science, talent, and collaborativeminds around the world to achieve our mission.

Through a proven and prolific internal discovery
engine and strategic external collaborations, we

15 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

partnered to advance an ADC therapy forpatients with solid tumors. ADCs embody

our solid tumor portfolio, we are advancing
World Health Organization. World Cancer Day: closing the care gap. Available at: https://www.
who.int/news/item/03-02-2022-world-cancer-day-closing-the-care-gap
3
Cancer Research UK. Worldwide cancer statistics. Available at: https://www.cancerresearchuk.
org/health-professional/cancer-statistics/worldwide-cancer#heading-Zero
4
This goal was adjusted from the 2022 Report to better align with our focus on advancing only
the most high-quality molecules into the clinic.
5
DOI: 10.1200/EDBK_390094 American Society of Clinical Oncology Educational Book 43 (May25, 2023)
2

several internally discovered ADCs to bringthe most innovative medicines to patients.

Introduction

Our Approach

Our portfolio is currently built around two foundational

patient pools, enabling us to complete patient

Our Development Core Teams—including individuals

enrollment more quickly

from clinical development, clinical operations,

Enrolling patients in countries and regions thatclinical pharmacology, and regulatory, among

have often been excluded in oncology trials,

others—are responsible for the Clinical Development

leading to greater patient diversity and cost

Plans (CDPs) for each product candidate. Each CDP

savings

includes an assessment to identify potential risks

To date, we have planned trials or enrolled
patients in more than 45 countriesof BeiGene’s solid tumor portfolio, thisAppendixas centerpieces of an expansive combination

45+

antibody. As TEVIMBRA is the cornerstone

OperatingResponsiblyassets, BRUKINSA and TEVIMBRA, developed

Clinical Trial Efficiency

TEVIMBRA, an anti-PD-1 monoclonal

Innovating
Sustainably

instills confidence among clinical trial participants.

development pipeline on our website.

to develop, manufacture, and commercialize

Empowering
Our Colleagues

Recruiting patients in countries with large

strategy. To read more about our pipeline, visit our

In 2023, BeiGene regained the global rights

AdvancingGlobal Health22,000+To date, more than 22,000 patients6 haveenrolled in clinical trials with BeiGene assets

development empowers us to continue

to patients and plans to mitigate those issues. We
We also continuously internalize and improve ourassess the overall benefits and risks of each newclinical-trial processes, allowing us to have moretherapeutic candidate considering current andcontrol over the process, which results in increased

expected treatment practices for a given indication.

efficiency and lower risk.

Each CDP is reviewed by a Development Review
Committee, which is chaired by a Vice President

We are currently conducting approximately 90

and/or Executive Committee member and includes

clinical trials. These include clinical trials in the U.S.,

senior development leaders from across the

Canada, Australia, South Africa, China, South Korea,

company.

and countries across Europe, as well as countries
that have often been excluded in oncology trials

Every CDP includes strict guidelines for protecting

such as Brazil, Mexico, and Argentina. In Brazil,

patient safety and privacy in accordance with ourour efficiency and focus on quality submissions,internal policies and standards and in alignment

coupled with our local site start-up and regulatory

with regulatory and international standards. This

exploring TEVIMBRA’s full potential to

As part of our continuing commitment to developing

expertise, have resulted in quick approvals ahead

includes obtaining the informed consent of eachaddress unmet clinical needs around theinnovative medicines, we have built an internalizedof the standard 180- to 210-day approval timeline.

patient participating in our trials, as well as providing

world, including in combination with ourglobal clinical-development organization guided

Executing these trials strategically and efficiently

adequate information about the research study

deep and diverse solid tumor pipeline,

by our mission to ensure that patients around theenables us to start enrollment faster, positioning us

and its potential benefits and risks. Our approach

which has several immuno-oncology andworld have access to innovative life-changing

to get medicines to market and to patients in need.

empowers patients to make an informed decision

targeted molecules that could be paired

medicines. With the expansion of our team, wewith TEVIMBRA. This furthers our mission

ensure better control over quality, speed, cost, andof expanding patient access to innovativerisk, as well as higher levels of engagement with site

medicines and addressing areas of highinvestigators of BeiGene-sponsored clinical trials.

For every investigational medicine, we follow a

investigative techniques in our quest to develop new

unmet need for patients around the world.

Our ability to accelerate clinical trials is due in part tostructured and formal process for governing andtherapies and is committed to conducting

our broad geographic reach, which can result in cost

executing clinical trials. Our standardized processsavings by:

ensures the integrity of clinical trial results and

16 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

about their participation in the clinical investigation

Clinical Trial Excellence

and requires their voluntary agreement to participate.
BeiGene’s research team deploys several

6

Number of patients include those in Investigator Initiated Trials (IITs)

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

our research studies and clinical trials responsiblyand ethically. Our bioethics program provides a

Data-Cleaning Pilot Program

framework to guide internal decision-making,helping us deliver on our mission with integrity.

As part of our efforts to drive quality and efficiency in our trials, BeiGene

Additionally, BeiGene is committed to the humane

launched a pilot data-cleaning program for our trial databases. While theand ethical treatment of any animals utilized in ourstandard timeframe for updating our database is four weeks, this program

research and has policies and procedures in placeallowed us to close our database log in just a single week. Providing quality

to ensure high ethical standards are maintained. Ourdata is key to our work, and cleaning trial data quickly and efficiently while

approach to bioethics and animal welfare is further

maintaining accuracy optimizes our progress. Moving forward, BeiGene isoutlined in Our Policies, page 54.

working to establish this as the new benchmark for our teams.

Clinical Trial Transparency &Sharing of Research Data
Clinical trial transparency and the sharing of ourcompletion date (or study completion/end of study

submission and approval in the U.S., China, andevents. In North America, we attended over 30

clinical trial data support biomedical innovation,

when primary and study completion dates are

Europe. Clinical trials supporting subsequent local

events, including The Leukemia & Lymphoma

increase broader awareness of clinical research, andthe same) on applicable websites in complianceapprovals, new indications, or combination productsSociety’s Blood Cancer Conference and thefoster public trust in our products and treatments.

with regulatory timelines and policy expectations.

are eligible for sharing once corresponding regulatory

International Waldenström Macroglobulinemia

We proudly commit to the Biotechnology Industry

For select studies, BeiGene may delay results

approvals are achieved. BeiGene shares data only

Foundation Education Forum, among others.

Organization (BIO) Principles on Clinical Trial Data

submission to protect intellectual property, business

when permitted by applicable data privacy and

BeiGene also attended seven European-based

Sharing and the responsible sharing of our clinicaldevelopment, or publication needs. In support of

security laws and regulations. In addition, data canpatient conferences and events, along with 25 intrial data to advance such research. To this end,

related disclosure requirements, BeiGene publishes

only be shared when it is feasible to do so without

greater Asia Pacific and 10 in new markets.

BeiGene registers Phase 1 through 4 interventional

clinical study documents on applicable websites. For

compromising the privacy of study participants.

trials and applicable non-interventional studies

select studies, BeiGene provides a plain-language

on publicly accessible websites like ClinicalTrials.

summary of the study design, objectives, and results

gov, BeiGene’s clinical trials website, and others inthat is understandable to individuals without medical

accordance with regional and national regulatory

training or scientific knowledge.

requirements around the world, as well as theAdvancing Diversity in Clinical Trials
Medical Education & Research

Enrolling diverse candidates in clinical trials is

BeiGene supports educating healthcare

important to advancing health equity. Requiring thatprofessionals on our medicines, innovations inclinical studies include people of different races, ages,

BeiGene Data Disclosure and Transparency

BeiGene voluntarily shares data on completed

drug development, and new approaches to patient

genders, and ethnicities ensures that more people

Policy, which is expected to be made publicstudies responsibly and provides qualified scientificcare. This includes sharing research findings at

benefit from innovative, efficacious, and safe therapies.

in 2024. BeiGene discloses results of Phase 1

and medical researchers access to data andconferences and congresses, as well as sponsoring

through 4 interventional trials and applicable non-supporting clinical trial documentation for clinicalscientific meetings globally. In China, BeiGene

By taking a globally inclusive approach—andinterventional studies 12 to 36 months after primary

trials in dossiers for medicines and indications after

sponsored over 2,000 education and research

integrating the voice of the patient—we are

17 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

broadening access to clinical trials to discover

relationships with key oncology research centers

To better support our clinical and corporate goals,

treatments that meet the needs of more people

and nonprofit organizations, such as CATALISEPEPS works with internal and external experts

living with cancer. We have built a predominantly

Québec.

in patient engagement to develop our patient

in-house clinical development organization focused

engagement strategy. Our strategy seeks to ensure

on developing a pipeline of innovative therapies

We are also exploring potential partnerships witha person’s lived experience and expectations arefor more patients and thus prioritize partnering

medical schools of Historically Black Colleges andreflected in BeiGene’s drug development andwith diverse patient communities for our key R&D

Universities (HBCUs), Hispanic Serving Institutionscommercialization, as this is central to providing

programs to expand the reach of our clinical trials to(HSIs), and local communities, which deepen ourmeaningful treatments to patients. Additionally, ourunder-represented communities.	

understanding and further our reach with under-

Patient Engagement Guidebook provides details

represented patient populations.

on the strategy and a robust roadmap on where,

In 2023, our cross-functional Global ClinicalDevelopment Planning Working Group developed
our comprehensive diversity strategy and goals in

Innovating
Sustainably

OperatingResponsibly“We are proud to have laid such astrong foundation for thisimportant work, which will guide
us in the years to come. Our longer-term goal
is to establish BeiGene as an industry leader
in patient engagement, elevating patient andcaregiver insights in our R&D, embedding thepatient voice in BeiGene’s DNA, and further
elevating our core valueof Patients First.”

why, and how best to include patient insights in thePatient Engagement

line with the regulatory requirements establishedTo further develop the best oncology treatments

by the U.S. Food and Drug Administration (FDA).

for our patients, BeiGene orchestrates high-quality

To achieve our clinical diversity goals, BeiGene

clinical trials. We focus on not only expandingis writing and submitting inclusive protocols andpatient diversity in our trial enrollment but also

CDPs to registration-enabling trials and conducting

developing clinical trials that meet patients’clinical trials in geographies beyond major healthneeds, address accessibility issues, and support

centers. This approach enables us to reach under-

better outcomes. To achieve this, we seek patient

represented patient populations. Expanding

engagement from the earliest R&D stages andenrollment can also expedite patient enrollment,

when developing our clinical trials.

which may result in reducing time to market.
Our Early Patient Engagement and Professional
In 2023, BeiGene broadly expanded into theSocieties team (EPEPS) acts as facilitator andLatin American market, which includes several

relationship manager for all patient engagement

ethnicities, races, and people from diverse

activities relating to clinical trials. EPEPS works

socioeconomic backgrounds. Specifically, BeiGenealongside study teams to identify which program

has a total of six studies allocated across Argentina,

needs can be supported by patient engagement

Brazil, and Mexico.

activities and then devises a plan with the team
to collaborate on measurable success metrics.

In North America, BeiGene has expanded our clinicalThis approach brings patient insights into ourreach within the U.S. and Canada by establishing

R&D planning.

18 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTAppendix

pipeline at all stages of drug development.
– Tricia Mullins
Executive Director, Global Headof Early Patient Engagement
and Professional Societies

Introduction

Patient Safety
Upholding our value of Patients First, our Global
Patient Safety (GPS) team ensures the safe andeffective use of our medicines from their first use inclinical trials to prescribed post-commercializationuse. GPS, headed by our Chief Safety Officer,
comprises a global team of over 150 physicians,
safety scientists, and pharmacovigilance
professionals dedicated to characterizing thesafety of our growing portfolio, rigorously surveilling
patient outcomes, and effectively addressing safetyissues that may arise.
GPS maintains high compliance with therequirements and timelines of global regulatory
authorities and BeiGene’s safety protocols. BeiGene
quickly acts on any report of a suspected adverse
event (AE) or product complaint received fromclinical trial sources or spontaneously reported
from marketed use. To facilitate reporting ofadverse events, BeiGene maintains various
channels, including a newly implemented webformfor direct AE reporting, a dedicated patient safety
email address, and live call centers in Europe,
the Americas, and Asia Pacific. All establishedchannels enable AE reporting in seven local
languages, demonstrating BeiGene’s efforts toimprove safety data collection and the reporting
experience for healthcare providers and patients.
GPS also maintains an emergency response plan
to ensure the maintenance of routine functionsand GPS activities, including staffing plans and IT

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

system redundancies, in the event of local or
global disruptions.
BeiGene has developed a global standard operatingprocedure (SOP) and mandatory annual training for
all BeiGene colleagues to teach them how to reportadverse events, adverse drug reactions, special
situations, urgent safety measures, and productcomplaints globally for all BeiGene-marketed
products. GPS also maintains robust educationalseminars and resources available on demand by
the enterprise and runs periodic campaigns to bringawareness to relevant patient safety topics. These
resources, produced by pharmacovigilance experts,
bridge the regulatory environment we operate inwith best practices, knowledge, and behaviors tocultivate safety across our organization.
Using robust scientific approaches, our team utilizes
available data, epidemiological techniques, andknowledge of product-class effects to provide safety
oversight and expertise and to differentiate BeiGene
products. At every stage in the product life cycle,
our global pharmacovigilance system characterizes

Cultivating a Culture of Safetyand documents the safety of our medicines inalignment with the standards set by international

In 2023, the Global Patient Safety team created interactive learning materials to further

and local regulations, as well as BeiGene’s internal

educate BeiGene colleagues on urgent safety measures and ensure any colleague who

standards. Communications regarding our products’

receives safety information stemming from a clinical trial understands their responsibility

benefits and known risks are shared accurately andto immediately direct all information through our existing safety governance framework.

in a timely fashion via public labeling documents to

Developing these educational materials helps the GPS team live its commitment to patient

support regulatory filings and continuous productsafety every day and demonstrate internal and external standards for Driving Excellence.

surveillance.

19 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Pursuing Broad Accessto Our Medicines

AdvancingGlobal Health

Empowering
Our Colleagues

We leverage several methods to deliver our

In 2023, we grew our commercial team to

medicines to more patients globally, including:more than 3,700 members. Our approach

Innovating
Sustainably

OperatingResponsibly

Appendix

to rapid global expansion can be attributed


GOAL
Continue to seek approvals for our
medicines globally.

Our Approach

Expanding our commercial presence into the commercial success of our two

both established and growing markets

cornerstone medicines, BRUKINSA andtislelizumab. As of the end of 2023,



Demonstrating a collaborative and flexible

BRUKINSA is approved in over 65 countries

approach to pricing and reimbursement

and tislelizumab is approved in 12 indicationsin China and in the E.U. and U.K. with multiple• BeiGene medicines are approvedin more than 65 countries• 38 marketing authorization
applications in multiple indications
are under review around the world

Our approach to market access and commercialization
is guided by our value of putting Patients First.
All patients deserve high-quality, innovative, andour three impactful medicines regardless of theirgeographic location or socioeconomic status. To
ensure the greatest number of patients have accessto our medicines, we are working diligently to
expand our footprint rapidly in both established andnew markets.

1 million+
BRUKINSA and TEVIMBRA havetreated more than one million patients

Offering assistance, including low- or

global approvals expected in 2024. We also

no-cost medicines, to eligible patients in certain

have 38 marketing authorization applications

markets where permissible

in multiple indications under review around

Improving Access forPatients in China

the world.
In December, China’s National Healthcare Security

Expanding Our Commercial
Presence

Beyond the discovery, development,

Administration (NHSA) released the 2023 Nationaland commercialization of our internallyReimbursement Drug List (NRDL), which included all 17

Many companies take a tiered approach todiscovered medicines, we seek to work withapproved indications for 3 of our internally developed

medicine registration, seeking approvals inorganizations that share our patient-centric

medicines: BRUKINSA, tislelizumab, and pamiparib.

developed markets that can yield the mostvision and our commitment to exceptional

economic gains before seeking registration inscience to ensure that, together with ourRelated to our in-licensed products, BAITUOWEI andmiddle- and lower-income countries. To protect

partners, we can get treatments to those in

SYLVANT were included in the NRDL for the first time,pricing structures, they may also forego sellingneed. We currently have partnerships withand XGEVA is now listed in Category B medicines with

their medicines in certain markets. But knowing

6 organizations to provide 14 products toan additional indication.

that cancer affects people in every corner of thepatients in China to enable quicker accessworld, BeiGene takes a different approach: weto innovative medicines. To date, 1.8 million

As more products and indications are included in theseek registration of our products across many

patients in China have been treated as a

NRDL, more patients in China will be able to havegeographies simultaneously, including bothresult of BeiGene’s commercial efforts.

better accessibility and affordability of the world’s

developed and developing markets, early in theleading oncology medicines. This progress is critical incommercialization process. Additionally, with ouradvancing our mission to create impactful medicines

broad global clinical trial reach, we ensure ouraccessible to cancer patients around the world.

pivotal studies can be used in regulatory filings
across markets.

20 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Global Approach to Affordability
At BeiGene, we work closely with health systems
globally to uphold our vision that price will not
be a barrier to patients’ sustainable access to our
medicines. Our Approach to Affordability guides
our practice of commercializing medicines withpatient cost in mind. When determining the price ofour medicines in a particular country, we consider
the health system’s financial resources and thevalue our therapies bring to a broad range ofstakeholders (patients, payors, and society). We

Our Approach

medicines across various markets. In 2023,

In addition to our expanded access programs,

BeiGene initiated new PRAPs for patient groups

through our myBeiGene program, we provide

in Italy, Belgium, Portugal, the U.K., Australia,

eligible patients in the U.S. and Canada

and South Korea, providing access several

reimbursement and coverage support, copay

months ahead of the final reimbursement

assistance, and free medicine to increase accessapproval. Additionally, we have extended theseto BRUKINSA. Beyond reimbursement and financial

PRAPs into emerging territories such as Israel,

support, myBeiGene also provides access to

as well as various countries in the Middle East

oncology nurse advocates that provide personalized

and Africa.

patient and caregiver support, including educational

Compassionate Use (CU): Our global CU

and additional resources and services such as

program is a testament to our commitment tocounseling and support groups.

cannot participate in clinical trials and lackalternative therapies. In 2023, BeiGene’s CU

Expanded Access Programs

program encompassed three investigational
drugs, benefiting more than 300 patients across

In situations where patients may encounter a lackapproximately 20 countries.

of clinical trial availability and standard distribution

ethical and regulated manner, in accordance withlocal legal requirements, for patients sufferingfrom life-threatening diseases without alternative
treatment options. More than 1,000 patients havereceived treatment through the EAPs across 30

Appendix

30 Countries
Patients received treatment throughEAPs in 30 countries

Improving Access for
Chronic Lymphocytic
Leukemia (CLL) Patients

Post-Trial Program Supply: BeiGene recognizes

Another way we ensure more patients living

the gap that can occur post-clinical trial andwith cancer have access to life-saving

is committed to bridging it. For patients who
have finished participating in a confirmatory
BeiGene-sponsored study and are waitingfor official product approval or availability, weoffer continued access to BeiGene treatments

1,000+
More than 1,000 patients received
treatment through EAPs

medicines is through our work with The
Max Foundation. Through this partnership,
BeiGene will donate our BTK inhibitor and The
Max Foundation will leverage its expertisein low- and middle-income countries andat no cost. This support is extended until the

global infrastructure to bring this medicine totherapy is granted local regulatory approval andaccess-limited patients living with CLL. This

Pre-Reimbursement Access Program (PRAP):

becomes broadly accessible. Currently, patients

partnership will begin providing treatment toThrough PRAP, we expedited access to

can obtain two of our medications in eightpatients in 2024.

BeiGene-approved medications for more thancountries through this program.

countries. BeiGene EAPs include:

OperatingResponsibly

before regulatory approval for patients who

delivering high-value medicines.

free-of-charge access to our medications in an

Innovating
Sustainably

providing access to investigational medicines

geography, and minimize the cost of care while

Access Programs (EAPs). These EAPs facilitate

Empowering
Our Colleagues

materials, connection to advocacy groups,

aim to go where our patients are, regardless ofconstraints, we have initiated several Expanded

AdvancingGlobal Health700 patients, broadening the availability of our

21 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Advancing Global
Health Equity
In 2023, BeiGene laid the foundation to be a leader

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

as a founding sponsor to support its Fellowshipin Regulatory Science, Innovation, and Health
Equity program.


Activating Equity Across BeiGene. We

in global health equity (GHE). We developed aensure that our colleagues around the world

vision and mission for this commitment that reflects

understand and support our GHE commitment,

the voices and needs of at-risk patients, defined

are committed to advancing equity among

what “global health equity” means to BeiGene as

our colleagues, and that our company has

a company, and launched the Advancing Global

the organizational capabilities—including the

Health Equity website page. We also formed

talent—to fulfill this commitment.

a global, cross-functional working group, withexecutive leadership and Board of Directors



Supporting Healthy Patients & Communities.

oversight, to focus on developing our strategy,

We promote health in our patients andgoals, and approach to global health equity.

communities through initiatives such as Talk
About It, our U.S. educational campaign focused

The vision for our GHE commitment is to breakon cancer and mental health; the myBeiGenebarriers and transform lives through equitablepatient support program; and the BeiGene

access by focusing on the following platforms:

Foundation, which works to eliminate barriers toequitable and accessible cancer care in under-Advancing Inclusiveness in Research &represented communities around the world.

Clinical Trials. We partner with diverse patientcommunities early and often in our research

In launching this work, BeiGene is planning towork—including clinical trials—to provide

establish a Health Equity Patient Leadership Council

therapies that are safe and effective for moreand expand its partnerships with organizations topeople living with cancer.

address the global burden of cancer and equitable
access to care.



Building Transformative Partnerships. We
partner with more than 20 patient advocacy
organizations, collaborate with The Max
Foundation to increase access to treatment, andwork with the FDA’s Reagan-Udall Foundation

22 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTHow BeiGene Defines Global Health Equity
Global health equity is a business priority and social imperative at BeiGene. We believe that
where a person lives, their race or ethnicity, gender, age, disability status, sexual orientation,or any other factor that can be used to minoritize or marginalize an individual should not
impact their ability to access their highest level of health and well-being possible.

Introduction

BeiGene Foundation

GOAL
Establish and launch BeiGene Foundation• Launched the BeiGene Foundation,a 501(c)(3) organization, andsubsequently donated its first grant to
The Max Foundation

The BeiGene Foundation was launched in early

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

BeiGene has always been acompany that understands
that to make a real impact inthe world of oncology, we must do morethan just develop medications. We mustalso positively impact our communities,
where our colleagues and patients live
and work. It has been exciting to see theestablishment of the BeiGene Foundation
alongside the expansion of our global
volunteerism program come to fruition
within the same year.

2023 as an independent 501(c)(3) organization
to provide grants to charitable organizationsaligned with the Foundation’s mission. The
BeiGene Foundation is led by the Executive
Director of Responsible Business & Sustainability
in partnership with the Board of Directors of
the BeiGene Foundation, which is responsible
for approving grants. In May, the BeiGene
Foundation made its first grant in support of The
Max Foundation as part of a collaboration with

I am further encouraged to see ourcolleagues exceed 20,000 volunteer
hours in the first six months of ourprogram. So many colleagues jumped
at the opportunity to organize andsupport causes close to them. I’m proudthat our organization has built a culture
in which colleagues actively live ourvalues and mission.

BeiGene to deliver medicine free of charge topatients in underserved markets. To read more

The BeiGene Foundation Mission
The BeiGene Foundation is a nonprofit dedicated to eliminating barriers to equitable and accessible
cancer care in underrepresented communities around the world. By expanding cancer healthcare
services, supporting community-based solutions, and scaling programs working to break cycles ofinequity, we are creating a healthier and better world for all.
The Foundation expands beyond BeiGene’s mission of providing the highest quality therapies toabout The Max Foundation collaboration, seemore people around the world by providing funding to support charitable, community-engaged

page 21.
—Christine Riley Miller,
Executive Director of Responsible
Business & Sustainability

23 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

programs in three strategic areas:

Access to equitable cancer healthcareCommunity engagement



Disaster response

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

BeiGene Sponsors Reagan-Udall
Foundation for the FDA
BeiGene is proud to sponsor the Reagan-Udall Foundation’s
Fellowship in Regulatory Science, Innovation, and Health
Equity for a second year. The fellowship seeks to increase
diversity in regulatory science by offering opportunities
for individuals with varied life experiences to begin acareer in regulatory science and build lasting professional
relationships among FDA stakeholders.
BeiGene supported the pilot fellowship program in 2022
which aided in the development of medical products
suitable for pregnant and lactating women, with a heavy
focus on addressing health equity issues through the project.
In 2023, Howard University, an HBCU* and one of the nation’s
leading research universities, assisted with the design ofthe fellowship program and the selection of the 2023 and2024 fellows. There is a great need to advance health equity
within the regulatory science workforce. Advancing diversity
in regulatory science contributes to more meaningful results
for the communities and patients impacted and ensures ahealth equity lens is integrated into this important work.

*Historically Black Colleges and Universities

24 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTAppendixIntroduction

Supporting Patients

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

provide important patient insights and feedback to
inform our clinical development and commercial

GOAL

programs.

Spearhead multi-stakeholder solutions
that empower patients and disrupt
systemic access barriers by 2025

In each geography we enter, the PAOs we partner withand the local patient communities they support haveunique needs, capabilities, and resources. Recognizing
their differences, we work within each geography to• Partnered with patient organizations togain patient insights in our clinical studies

broadly address health equity for oncology patients.

• Finalization of the Patient Engagement
Guidebook to provide a robust roadmap on
where, why, and how best to include patient
insights into the pipeline at all stages of drug

opportunity to be transformative in our impact as wedevelopment

Our partnerships with these PAOs offer us a critical
help them expand their advocacy capabilities for theirdiverse populations. In return, these partnerships will
enable us to increase the input of diverse patients in our
research and clinical trial plans and design, as well as
increase the number of diverse patients and caregivers

Patient Advocacy

who receive education about clinical trials (seeAdvancing Diversity in Clinical Trials, page 17).

BeiGene is at an important inflection point as aninnovator and global leader in oncology. To increase ourOur commitment to the highest standards of integrity

impact, we are uniquely positioned to amplify the voices

and adherence to industry codes and relevant lawsof our patients to better understand their unmet needs,

relating to patient engagement and advocacy includes

determine how we can prioritize those needs, andhonoring the independence of PAOs in their politicalimprove the policies that shape the oncology ecosystem.

judgment, strategies, policies, and activities; neverIn 2023, BeiGene colleagues volunteered in many PAO-sponsored events globally.

requesting that a PAO promote a prescription-only

As a national sponsor of The Leukemia & Lymphoma Society’s Light The Night

Patient advocacy organizations (PAOs) support patient

medicine; ensuring that the objectives and scope ofin the U.S., 239 individuals representing BeiGene joined more than 25 teams

needs by providing resources, information, andour partnerships are transparent; and that financial or

to raise money for the cause and attend local Light The Night walks across theeducation programs to patient communities and medical

non-financial support is clearly acknowledged. For more

U.S. Together, BeiGene’s teams raised over $40,000 to support The Leukemia

professionals. To support their efforts to elevate patient

information, please see Our Global Policy Position on& Lymphoma Society’s mission and work. BeiGene will significantly expand its

needs, we have established strong relationships with

Partnering with Patient Organizations.

support in 2024, serving as National Presenting Sponsor of Survivorship and Hopeseveral PAOs globally and are building new partnerships
as we enter additional geographies. These partnerships

25 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

for Light The Night across the U.S.

Introduction

Supporting the Well-Beingof Patients
A cancer diagnosis can be difficult to navigate, from

Our Approach

Launched a central resource for cancer andmental health at cancerandmentalhealth.com.



Hosted Talk About It panel discussion events

understanding treatment options to coordinating

during the American Society of Hematology

transportation and care. To help patients and theirannual meeting, increasing the number ofcaregivers, BeiGene partners with PAOs to educate

participants from more than 40 advocatespatients and caregivers about the disease, options

representing 18 U.S. and global PAOs at the 2022

for treatments and trials, and other available

event to over 50 advocates representing 27

supports. As a result of this work, BeiGene identified

global PAOs in 2023.

a significant gap in resources to address the mental
health needs of cancer patients. To help close thiscritical gap, BeiGene sponsored a study in 2022 with
Cancer Support Community (CSC) of over 600 U.S.
cancer patients. This research further highlighted
these concerns and inspired the foundation of
BeiGene’s program, Talk About It: Cancer and Mental
Health.
Talk About It increases awareness of the relationshipbetween cancer and mental health and theimportance of addressing mental health to improve

Sponsored the national, “A Call to Action:
Delivery of Psychosocial Care in Oncology
Summit,” in Washington D.C. in partnershipwith the Association of Community Cancer
Centers (ACCC) and its partners, the Associationof Oncology Social Work (AOSW), and theAmerican Psychosocial Oncology Society(APOS). The summit centered on addressing
barriers to timely and appropriate mental
health care for cancer patients and caregivers
experiencing psychological distress.

patient health outcomes. The program also curates
resources that support and educate people living

In 2024, BeiGene plans to expand Talk About It intowith cancer, their caregivers, healthcare providers,

Australia and Canada and focus on the integration ofand advocates. In the program’s first year, we:mental health support into clinical trials.



Established three partnerships in cancer andmental health with PAOs.



Hosted four Talk About It webinars with morethan 300 registrants representing over a dozen
PAOs, HCPs, patients, and caregivers.

26 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

Empowering
Our Colleagues
Our vision to transform the biotechnology industry andincrease access to innovative cancer treatments aroundthe world begins with the strength, commitment, and talentof our people. Our values of Patients First, Bold Ingenuity,
Collaborative Spirit, and Driving Excellence drive our work
forward and enable us to attract a talented and motivatedIn this chapter,
we share our approach to:
Building Our Team
Colleague Engagement & Support

workforce of top medical and business professionals.

Compensation & Benefits

Together, we have fostered a culture of innovation, mutual

Career Development

respect, and belonging, which amplifies our impact as we

A Culture of Belonging

work toward our ambitious goals.

Employee Volunteerism
Health & Safety

27 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Building Our Teamwith family care responsibilities, and individuals

2023 with a team of over 60. These new colleagues

Our four state-of-the-art laboratory sites and threewith temporary health conditions. We believe if

support the clinical operations and new market

manufacturing plants in China and the United States

BeiGene is proud of our ability to attract and expand

individuals can meet the position’s requirements

development teams. Europe’s headcount increased

have been renovated and expanded, reflecting ourour global teams to meet our ever-evolving needs.

and goals, they should have the opportunity

by approximately 50%, from a little over 400

dedication to innovation and production excellence.

In 2023, we added more than 1,250 new colleagues

to contribute to our mission. Our flexibility andcolleagues to 600 by the end of the year. The Asia-

Our hybrid working style allows our home officeacross five continents, which increased ourcommitment to colleague success have attracted

Pacific region, excluding China, grew in parallel with

network to flourish as well, with thousands of

employee base by approximately 14% to more than

top-tier talent, including more than 1,000 MDs andEurope, with a growth rate of over 35%, from morecolleagues working remotely in 32 countries.

10,000 colleagues worldwide.

PhDs globally.

than 250 to over 350 colleagues, as the commercial
and clinical operations teams continued to expand.

To grow our global team, we tailored our recruitment

Combined with headcount growth, our physicalIn the U.S., headcount increased by 18%, from 1,300

strategies to meet the specific needs and dynamics

presence has solidified around the world, withto more than 1,500 colleagues.

of each region and function while keeping costa strategic expansion that underscores ourefficiency and time-to-fill rates in mind. This included

commitment to being a truly global oncology

leveraging online platforms, promoting internal

leader. In 2023, we celebrated the opening ofreferrals, running college campus campaigns,

new local offices in Canada, Belgium, Brazil, andattending job fairs, utilizing targeted advertising,United Arab Emirates. We also entered Portugal,

and partnering with local recruitment agencies

Thailand, Malaysia, Argentina, and Colombia,

to attract candidates from different regions.

enhancing our global agility and connectivity. This

BeiGene’s recruitment process assesses not only

geographical diversification not only brings us

the candidates’ skills and experience but also

closer to our patients and partners but also enriches

their alignment with our core values. We look forour corporate culture with a wealth of diverse

candidates who demonstrate a commitment toperspectives and expertise.

patient well-being, a willingness to challenge thestatus quo, a spirit of collaboration, and a drive for

In 2023, the region with the largest growth

excellence. This value-driven approach to candidateby headcount continues to be China, with theevaluation helps us identify individuals who will

addition of over 650 new colleagues—a growth

thrive in our culture and contribute to our mission.

rate of 9%. This year, China focused on expanding
both technical operations and manufacturing

We recognize that our teams consist of individuals

and research functions by approximately 20%,with different needs and life circumstances. Our

which contributed to more than two-thirds of theremote and hybrid work options, as well as part-time

total headcount growth in China. Latin America

opportunities, allow us to attract a diverse range

experienced the most significant growth, startingof candidates, including working parents, thosethe year with just eight colleagues and closing out

28 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Colleague Engagement& Support
As a company with a mission to create positive

Additional survey insights included:88%

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

The survey results also showed that BeiGene has

Innovating
Sustainably

1.

OperatingResponsibly

AppendixCompany Focus: Strengthening ourroom to grow in our support for work-life balance.

work processes through automation andWhile the global score remained high, with 78%

technological solutionsof colleagues saying BeiGene has a good work-

2.

Team Focus: Establishing clear expectations

life balance culture, we did not meet our goal toaround meeting effectiveness, roles andimprove work-life balance survey scores by 3%

responsibilities, and autonomy; understandingin 2023. As BeiGene is committed to supporting

the meaning of “Work Better, Live Better” forWe foster open communication across all levels,

balance for our colleagues, leadership took these

employees; and discovering how managers canmaintain an open-door policy so colleagues canresults seriously. They began working to enhance

support their goals for balanceseek support and counsel from their managers

our work-life balance program, relaunching it as achange in society, we work hard to cultivate aculture that does the same for our workforce.

and other leaders, and actively encourage ourcolleagues to share their points of view andexperiences in meetings and workplace forums.
In this way, our colleagues feel empowered to
grow both personally and professionally whileof colleagues agreed they are proud towork for BeiGene84%

of colleagues agreed that BeiGene
motivates them to go beyond what theyexperienced in a similar role elsewhere

also being inspired by the impact we have on the
lives of our patients.
In 2023, we conducted a Work Better, Live Better
Pulse Survey to gauge colleague engagement
and sentiment on our culture. We were happy to
see that our engagement score remained very

85%of colleagues agreed that their
manager helps set a clear strategy forthem to achieve their goals

high at 83%—on par with the 84% engagement
we measured in our 2022 global engagement
survey. Our colleagues collectively expressedsatisfaction with the organization’s overall culture,
feeling that they are valued and appreciated bytheir peers and leaders. Furthermore, the survey
results suggested that our colleagues perceive
there are ample opportunities for career growthwithin the company.

84%

of colleagues agreed that BeiGene
supports their growth and development
and that they have access to thelearning and development resources
they need to perform their job well

29 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

3.

Colleague Focus: Providing resources andglobal “Work Better, Live Better” program with three

training to support individuals in building

distinct pillars:

proactive behaviors, creating efficiencies, andimproving well-being, while exploring what
employees need to feel their very bestIntroduction

Our Approach

Additionally, BeiGene continued to provide

We plan to conduct another global engagementcompany-wide incentives to promote a positive

survey in 2024, with an aim of maintaining our highWork Better, Live Better culture, including two

engagement score and a stretch goal to increase thecompany-wide quiet weeks, when meetings andscore by 3%. BeiGene is now committed to runningcalls are discouraged to enable colleagues tothe engagement survey every other year, while also

complete essential tasks related to their work as

conducting pulse surveys annually to maintain awell as their personal lives; Focus Fridays, whengood understanding of colleague sentiment.

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

meetings and calls are reduced in a colleague’s
local time to free up work time; and quiet hours
during local time to fully disconnect and make time
off meaningful.

69%

of colleagues agreed that “BeiGene’s
Work Better, Live Better Global
Initiatives are making a difference forme” in the 2023 Work Better, Live Better
Pulse Survey

We also know leadership behavior is essential to ateam’s Work Better, Live Better success. In addition

GOAL
Improve Work Better, Live Bettersurvey scores by 3%, with a stretch
goal of 5% in 2023

• Work Better, Live Better score wasmaintained, but did not improve

resources for them to support their teams in setting
expectations around work hours, time off, anddeadlines. Further, we created a cross-functional

In 2023, BeiGene Australia was recognized as one of the country’s top 50 Best Workplaces™
for Women in 2023 by Great Place To Work®. This was an honor, as Great Place To Work awards

GOAL

are determined based on rigorous independent analytics and substantial confidential BeiGene

Maintain colleague engagement scores
globally versus 2022 engagement scoreswith a stretch goal of +3% for the 2024
engagement survey

and camaraderie within the organization. BeiGene is built on the principle that our colleagues• We plan to conduct an engagement
survey in 2024 to track our progressagainst 2022 benchmarks

Australian colleagues celebrated the achievement, and many shared their thoughts as toto encouraging leaders to model healthy balance
to their teams, we continued to provide training and

BeiGene Australia Awarded Top 50 Great
Places to Work for Womenand regional task force that will drive this work in
2024 by exploring our work processes globally andconsidering solutions that utilize automation andtechnology to support our goals.

30 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

employee feedback, which demonstrated high levels of trust, respect, credibility, fairness, pride,
are our most valuable assets, and we firmly believe that how we work is just as important as thework we do. We are proud to have built a community and culture in which colleagues can findbalance and where women feel empowered both professionally and personally.

why BeiGene deserved this award, including Betty Wanting Zhu, Senior Financial Planningand Analytics Manager, Asia Pacific: “I feel BeiGene’s values around creating equal access tocancer treatments is translated into the work culture, with everyone being given fair and equal
opportunities. Perhaps because it’s a relatively young company, BeiGene has always felt
ahead of the curve here.”Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Compensation & Benefits

BeiGene Program

Details

At BeiGene, we value our colleagues’ personal well-being and care

EAP – Employee Assistance Program

Program provides work-life and mental health resources for colleagues, including free therapy
sessions for colleagues and family members.

Modern Health

Platform offers mental well-being resources such as coaching and therapy, on-demand self-help,
and community education and forums. Colleagues and eligible family members have access to
six coaching and six therapy sessions per year. This access is virtual and readily available.

HeadspaceApp provides resources for mindfulness, meditation, sleep, movement, and more, including
navigation to individualize the experience.

Virgin Pulse

Platform allows colleagues to engage in activities and fitness programs through company-wide
challenges with gamification for reward opportunities.

ThrivePass

Program provides two types of benefits: the Lifestyle Spending Account allows colleagues to getreimbursed for a variety of expenses related to health and wellbeing; the Tuition Reimbursement
program allows for reimbursement for courses relating to one's career.

CarrotProgram provides help and monetary support for family forming, planning, and hormonal health,meant to meet colleagues at every stage of life.

Care.com

Platform supports colleagues by connecting them with trusted care providers for their children,
seniors, and pets. Some countries allow for a back-up care subsidy.

AccessHope

Program provides access to cancer support services for colleagues and family members, including
expert second opinions on treatment plans and guidance through treatment to ensure success.

about their perspectives and goals. By taking a holistic view of wellbeing—one that considers financial, physical, and social-emotional
health—we are working to cultivate a community and culture where
our colleagues can find balance both professionally and personally.
We recognize the incredible talent and dedication of our colleagues
and seek to reward their hard work with competitive compensation
and benefits that support their overall well-being. As we expand in
numbers and geographies, we continually evaluate our offerings
to ensure our benefits are competitive, equitable, and inclusive
across regions and industries. Our total rewards structure begins
with a competitive base salary and provides all colleagues with theopportunity for annual performance incentives, generous equity
grants, paid time off, and other benefits specific to the needs of eachmarket, such as comprehensive healthcare coverage.
We assess benefits across our full workforce yearly to ensure weare competitive with changing market conditions. For example, we
increased 401(k) contribution matching in the U.S. to 6% to align withindustry norms and expanded our mental health and well-being
benefits (see more detail in the accompanying chart). We routinely
review our benefits offerings to ensure we are supporting colleagues
in all life cycle stages and support the needs of minority groups, suchas the LGBTQ+ community, colleagues with disabilities, and others.
Details regarding regional benefits can be found on page 69-70.
To learn more about the benefits that support our colleagues, visit
meetus.beigene.com.

31 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT*Programs may vary by region

AppendixIntroduction

AdvancingGlobal Health

Our Approach

All colleagues receive annual performance reviews,

BeiGene is committed to conducting internal pay

including peer reviews, 360 reviews, and managerial

equity reviews every two years in the U.S. We arereviews. These are opportunities for colleagues toproud that our analysis of data revealed no systemic

reflect on their contributions and achievements andpay equity issues in the U.S. As our headcountreceive corresponding performance incentives. We

grows, we will conduct pay equity audits compliant

also offer additional incentives for high-performing,with local legislation and continue to review our

high-potential colleagues. For instance, colleagues

processes to ensure all global colleagues are paid

at all levels are eligible to receive additional cash

fairly and equitably. For example, in France, we are

and/or stock awards for making contributions that

required to assess and report an index on gender

are business-critical to the success of BeiGene.

equality in the workplace. For 2023, we scored a

For unique one-off, business-critical situations, the98 out of 100, which is above the national average

CEO can grant an equity award to high-performing,

score in France.

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendixhigh-potential talent. In 2023, 70 equity awards were
granted under our CEO Key Contributor program.
In 2023, our median employee compensation was$77,568, including annual base pay, an annual target
cash incentive opportunity, and grant date fair valueof equity awards granted in the same year. Our
CEO Pay Ratio for 2023 was approximately 244:1, as
determined in accordance with the rules of the U.S.

Modern Health – A Better Mental Health& Well-Being Benefit

Securities and Exchange Commission (SEC).
In February of 2023, BeiGene added the Modern Health platform to the company’s benefits
BeiGene is firmly committed to equal pay for

portfolio. Modern Health provides BeiGene colleagues with a full range of mental health andequal work. As a pay-for-performance company

well-being solutions, including quick access to therapists, mental health and life coaches, andcommitted to pay equity, we embed policies,

self-driven well-being programs and tools. Colleagues and their family members have up to

principles, and practices of equity and inclusion

six free therapy sessions and six life-coaching sessions. These sessions can be used for any

across our processes, employee life cycle, andprofessional coaching that supports mental well-being, from productivity to public speaking toculture. Consistent with our BeiGene promise

career expansion. The platform’s programs and tools also allow for community formation, withstatement, we fairly compensate our colleagues

forums within the platform helping members support and encourage one another. BeiGene hasbased on the work that they perform.

seen great success and received positive feedback on Modern Health7.

732 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Modern Health is offered globally, with the exception of China, where the platform is not yet available.

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Career Development

their managers to craft plans to reach those goals,

We encourage all colleagues to draft an Individual

Because we believe that development is not limited

including on-the-job training and formal educational

Development Plan (IDP) in collaboration with theirto just training, we follow the 70-20-10 model: 70%

As our workforce levels have stabilized following aopportunities. As part of a global effort to align ourmanagers through our online development platform,

experience, 20% exposure, and 10% education by

period of rapid growth, we have shifted our focus

colleagues’ potential with the company’s mission andWorkday, which focuses on their professional

way of classroom training. While we offer a wide

to personnel development and leadership growth.

values, BeiGene launched our Global Competencies

development goals. We encourage our colleagues

assortment of classes, managers and colleagues

In 2023, we increased opportunities for colleagues

at our first Development Week in August 2023. Our

to direct most of their development hours to theirmust also work together to apply the skills in theto acquire valuable skills, grow in their roles at

Global Competencies stem from our four core values,

own development priorities. The introduction ofreal world through exposure and experience outside

BeiGene, and build their career paths for the future.

building a common language around how we work

the Global Competencies gave our colleaguesof the classroom. With an emphasis on real-world

and connect with others across all levels, regions, andthe ability to assess their gaps and seek feedback

application through our Global Competencies,

functions. They set a standard for what colleagues

from others through Workday to identify areas

our learning and development programs focus on

can expect from leaders, what colleagues shouldfor improvement. We believe that more frequentbuilding leadership capabilities, developing a culture

BeiGene encourages all colleagues to set

strive for in their own work, and a platform on which

informal feedback opportunities throughout the yearof clear communication, and promoting effective

professional development goals and work withto define development and success at BeiGene.

enhance colleague progress and individual career

teamwork across the organization.

Development Planning

development.
In 2023, the talent development team launched

Global Competencies

Fosters Teamwork
Provides and Solicits
Honest and Actionable
Feedback
Self-AwarenessActs Inclusively

Demonstrates Initiative

Results-Oriented

Entrepreneurial Mindset

Analytical Thinking/
Data Analysis

Continuous Learning

Financial Excellence

Embraces Change

Communicateswith Clarity

We also made strides in leveraging our internal

BeiGene University (BGU), a unified training platform

talent pool to fill open positions at BeiGene. Inthat allows the company to link all training platforms

2023, the percentage of positions that were filled

and offer personalized learning to our colleagues

by our current colleagues increased by threebased on their positions and individual goals. In

basis points. This improvement not only enhanced

addition to our standard classes in the BGU catalog,

opportunities for career advancement within thethe platform also facilitated over 170 customized

company, but it also strengthened our organizationalteam sessions globally on topics such as time

capabilities by leveraging the existing talent’s

management, design thinking, and storytelling.

institutional knowledge.

Additionally, BGU offers customized workshops
focused on tools such as DiSC, LPI 360, and Five

Education & Training Opportunities
As BeiGene expands, so do the professional

Behaviors of a Cohesive Team to build a common
language and understanding and promote a cultureof inclusion across our company globally.

development needs of our colleagues. We
Collaborative Spirit

Bold Ingenuity

33 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Driving Excellencewant every colleague, regardless of their level,

To capitalize on these learning opportunities,

to have the opportunity to learn, develop, andmanagers work with their direct reports to identify

flourish at BeiGene.

relevant skills and knowledge essential to specificIntroduction

Our Approachroles and to pinpoint development opportunities

leadership program. The 2023 pilot programfor colleagues to grow in those areas. For many

included 23 participants who were nominatedroles, training on topics like ethics, regulatory

as Key Talents. The program began with a Virtualcompliance, or environment, health, and safety

Kick-Off and Launch Pad to build community(EHS) are mandatory, while others focus on general

before participants attended an in-person, three-professional, management, or job-specific technicalday session on Leading for Change, Leading forskills.

Growth, and Leading Yourself & Others. Throughout

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

the three days, participants identified organizational
In 2023, we also kicked off our first global mentoring

opportunities and challenges and built cross-program. Our first cohort had 50 participants, andfunctional and cross-regional working teams.

early success helped us grow to 158 participants in

Afterward, these teams continued to work in

our second cohort. We plan to continue expanding

six-week sprints to develop solutions to thethe program in 2024. We also integrated our global

challenges they identified, and pitch proposed

electronic Learning Management System (eLMS)

solutions. Sprint Sponsors (BeiGene Executive

with Skillsoft, an on-demand learning resource that

Committee Members) provided advice and support

we launched in 2022. In 2023, more than 4,000

while expert consultants offered coaching and led

colleagues engaged in over 21,000 on-demandlearning webinars. Participants benefited from the

Skillsoft courses globally.

blended experiences of learning, practicing, sharing,and networking.

4,000+

colleagues engaged in over 21,000
on-demand learning and development
courses in 2023

The goal of this program was for participants tobroaden their view of the organization, enhancestrategic thinking, reinforce capability in facilitating
cross-functional and cross-regional collaboration,and be better prepared to face challenges andgreater responsibility when leading BeiGene’s future
growth. For more about leadership development,

Leadership Growthsee Succession Planning, page 52.

BeiGene Hosts First Annual Development Week
In late August 2023, BeiGene held our first global Development Week. The week started
with the formal launch of our Global Competencies and was packed with events, interactive
sessions, games, and more, all tailored to each region. More than 3,200 colleagues joined
the 72 virtual and in-person sessions around the world. The focus on professional, personal,
and technical development covered a wide range of topics, including work-life balance,
personal branding, leadership, and financial excellence. Most of the sessions were hosted by
BeiGene colleagues, who were excited to share their experience and passion for their area

BeiGene also offers advanced leadershipof expertise. The event was an opportunity for our colleagues to take a break from their daily

development programs for colleagues with highschedules and invest time in their career growth and personal development.

potential. In 2023, we launched LIFT (Leading
Innovation and Future Transformation), a global
cross-regional and cross-functional senior

34 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

A Culture of Belonging
As a growing, global, innovative organization, ourlong-term success and ability to compete globally
relies on building a culture and workforce thatembraces diverse perspectives and experiences.

GOAL
Reach global gender parity at the
VP level and above by 2030

This is what enables us to innovate and achieve
breakthroughs for patients.

• 38% of positions at the VP level
and above are held by women

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

As we continue to work toward our 2030 goals, we

our engagement surveys. In 2023, the Global IDEA

welcomed our new Executive Director of Diversity

Council, our employee council for the advancement

and Global Health Equity to lead our DEI&B strategy,of DEI&B at BeiGene, was relaunched as two

support our global health equity strategy, andgeographically separate IDEA Councils, one fordevelop BeiGene into a diversity-mature organization.

China and Asia Pacific and another for the Americas
and Europe. This split allowed for the inclusion of

Our DEI&B strategy, Belong@BeiGene, centers on

more colleagues on each individual council andbringing diverse voices to the forefront of our work

an opportunity to focus each council’s efforts on

and embedding inclusion in all aspects of BeiGene’s

geographically specific needs and goals.

operations. By building a culture that leverages“I am proud to join BeiGene’s
team at this pivotal moment inour growth. Our values andglobal reach allow us to draw from many
experiences while continuing to ensurethat equity and inclusion are at the centerof our work moving forward. We’re working
tirelessly to leverage the diversity of ourorganization to drive clearly definedoutcomes so that true health equity canbe realized. When we do this, everyonein the organization makes better decisions,and we see better outcomes for the patients
we serve.”—Julius Pryor III,
Executive Director, Diversity &Global Health Equity

GOAL

diversity and equitable principles in all aspects

The IDEA Councils continue to organize and supportof decision-making, we can drive clearly defined

our Coffee & Conversations programming—an

Achieve a 50% improvement inworkforce diversity (underrepresented
groups) company-wide at managementlevels in the U.S. by 2030

outcomes for both the business and our colleagues’

important platform for open, honest conversations

well-being. Our strategy encompasses three areas:that allows colleagues to share information andpersonal experiences around DEI&B-related topics.

1.

• Workforce diversity at managementlevels in the U.S. stayed consistentin 2023

Workforce: Advancing diversity maturity at

In 2023, Coffee & Conversations topics included

BeiGene by strengthening our recruitment,Intersectionality, Defining Health Equity, Challenges

development, retention, and succession

in the LGBTQ+ Community, Innovation & Change

programs and planningManagement, and Health Care Challenges in the
Hispanic community. We also launched unconscious

2.

Workplace: Shaping our culture to support

bias training to build understanding and awarenessGOAL

everyone in bringing their authentic selves toabout the impacts of bias on our colleagues.

Continue to improve the composition of
the Board of Directors for gender and U.S.
under-represented groups by 2030

and engaging colleagues to put forth new ideas• Efforts to enhance Board diversity
are ongoing

35 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

BeiGene by activating company-wide programs
To further inclusion and belonging, BeiGeneplans to launch our first Business Resource Groups
3.

Marketplace: Advancing diversity and(BRGs) in 2024. We have already establishedinclusivity in clinical trials and ensuring broad

steering committees for African American/Black,access to BeiGene medicines in underserved

Hispanic/Latino, and Women’s BRGs and plancommunities

to add additional groups for colleagues withdisabilities, veterans, and LGBTQ+, among others.

We bolster these efforts with continuous input fromWe also hosted the first BeiGene Annual Women’s

our colleagues through individual feedback andSummit in March 2024 where we announced thecorporate functions, such as our IDEA Councils andlaunch of our women’s BRG.

Introduction

In 2023, we maintained gender parity at all levelsof the organization below Vice President and madeOur Approach

Colleagues by Employment Type

AdvancingGlobal Health

Empowering
Our Colleagues

Colleagues by Region

Innovating
Sustainably

OperatingResponsibly

Colleagues by Age (%)

great strides in increasing women’s representationin leadership. At the Vice President level andabove, we saw the percentage of women increase
from 33% in 2022 to 38% in 2023. Additionally, thepercentage of total U.S. colleagues identifying as
members of under-represented groups increased
to 55%, in comparison to 52% in 2022.
As our current plans for 2024 include slowing thehiring trajectory BeiGene has experienced in recent
years, we anticipate that progress on our diversity
objectives will be minimal the next reporting period.

38%

of colleagues at the level of Vice
President and above identify as women,
up from 33% in 2022

36 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Colleagues by Gender (% Total)

U.S. Colleagues by Race and Ethnicity
in 2023 (% Total)

AppendixIntroduction

Employee Volunteerism

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

In 2023, we set a goal for our colleagues to donate
10,000 volunteer hours globally. We are proud

Our colleagues believe in our mission to create

to say that we surpassed this ambitious target,change in the world, and they carry this belief into

logging over 20,000 volunteer hours in support ofthe communities where we live and work, offering

local initiatives. BeiGene colleagues participatedimpactful support around the globe. BeiGenein charity walks, community cleanups, food drives,promotes these efforts to support our communities

and many other volunteer opportunities to reach thisand patients and was proud to launch both ourachievement.

corporate foundation as well as our global volunteer
program in 2023.

GOAL

Employee Volunteer Program

Engage colleagues in 10,000 hours
of global volunteerism by 2023

BeiGene encourages colleagues to share their
passions and lend their volunteer support toprograms that positively impact the quality of life
within their communities. In 2022, we piloted a new• BeiGene colleagues engaged inover 20,000 hours of volunteer
service globally in 2023

employee volunteer initiative in the U.S., allowing
colleagues to take a paid day off to volunteer for a
personal cause. At the beginning of 2023, BeiGene
expanded this volunteer paid time-off policy to allcolleagues around the world.
In July 2023, Be the Change, a global employee
volunteer platform, was officially launched with
BeiGene’s President and Chief Operating Officer,
Dr. Xiaobin Wu, as the executive sponsor. Throughthe Be the Change platform, colleagues learn about• Engage colleagues in 10,000 hours
of global volunteerism in 2024, witha stretch goal of 20,000 hours

GOAL

In 2023, the BeiGene Netherlands team came together to meaningfully give back to their

Expand volunteer paid time-off
policy globally in 2023

with Te Plastic Whale, the BeiGene Netherlands team boarded a small boat to collectvolunteer hours.

community by cleaning the Amsterdam canals of plastic and glass bottles. Partnering
plastic items, tin cans, bottles, and many other unusual objects from the canals, working
together to work toward plastic-free waterways. This volunteer event closely aligned

local and national community partnerships, create
or register for volunteer opportunities, and record

BeiGene Netherlands Fishes for Waste
in the Amsterdam Canals• Volunteer paid time-off policy
was expanded to include all
global colleagues

37 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTwith our Responsible Business & Sustainability priorities, furthering our progress toward
environmental sustainability and engaging more colleagues in volunteer-based actions.

Introduction

Health & Safety

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

At our BioIsland Campus, we established an

to meet biosafety requirements for all related

Beyond directly improving safety performance in

EHS committee consisting of the site head,operations, which included an oversight committee,

our manufacturing facilities and laboratories, we

BeiGene considers the health and safety of all

department head, and key colleagues frombiosafety SOP, biosafety risk pre-assessment,

also organized various EHS activities across these

our colleagues a top priority. In 2023, we hiredeach department to maintain a robust andemergency response protocols and drills,

sites in 2023 to support our robust safety culture.

a new leader to oversee EHS globally for all oureffective EHS management system within theequipment maintenance plans, and biohazard waste

This year, the Beijing and Shanghai laboratories held

location

disposal procedures and training to ensure safe

celebration activities to honor reaching 1,937,992

In our Suzhou manufacturing facility, we

handling of biological agents. In our Shanghai Lab,

safe working hours; Guangzhou manufacturing

our laboratory, clinical trial, manufacturing, and officeeliminated the use of acetylene gas in the QC

everyone who needed entry to a P2 lab received

celebrated 1,613,858 safe working hours; Suzhou’s

settings to ensure safety and standardized EHS

lab to reduce operational risks

additional special biosafety training and was

manufacturing facility celebrated 743,756 safe

In our Suzhou manufacturing plant, weapproved by the lab. At the BioIsland Campus, theworking hours; and the BioIsland Innovation Center

conducted regular health and safety risklaboratories were equipped with special biosafetycelebrated 175,776 safe working hours. The Suzhou

Our EHS system and strategy were established inassessment reviews to make sure our control

management personnel. We also organized threeplant also held a Health Week that included severalalignment with ISO14001 and ISO45001 standards.

measures were effective and to create a safe

cross-site training courses on biosafety to share bestsafety scenario practice exercises and a healthworking environment for colleagues

practices between our locations and teams.

workshop to promote healthy behavior for both

non-manufacturing and non-R&D facilities andestablished a global EHS standard strategy acrossexpectations for all colleagues.

To address both international regulatory standards
in our work, we developed several EHS programs

Both Suzhou and Guangzhou manufacturingpersonal and work life.

and trainings. In China, each manufacturing andfacilities obtained the ISO45001 certificate

Across our manufacturing and laboratory facilities,

laboratory site participated in training to improvein 2022

BeiGene’s total incident rate for 2023 was 0.05, withcolleagues’ awareness, knowledge, and safety

a lost time incident rate of zero. BeiGene did not

capacity. The training for colleagues at individualAs part of our EHS strategy rollout and improvement,

experience any work-related fatalities, had only one

sites covers the EHS-related topics needed to

we also launched MyEHS, a digital EHS system,

recordable accident, and no lost workdays due tomanage site-specific EHS issues, such as risk

to centralize EHS data collection and analysis,

incidents in 2023.

assessment, confined space entry, lockout andincluding reporting incidents, unsafe situations,tagout management, contractor management,

or conditions; requesting investigation; managing

incident management, and practices to reduce site

permits; and tracking environmental and safety

operation risk, and offers a methodology for how toindex management. To mitigate heavy equipmentbuild a safer and healthier workplace. Some site-

injury accidents, we also implemented Good Save in

specific actions include:

individual sites—a reporting program that engages

Both Beijing and Shanghai’slaboratories celebrated 1,937,992
safe working hours

0.05
total incident rate

colleagues in driving EHS culture.
Suzhou’s manufacturing facility
celebrated 743,756 safe working hours

In our Shanghai Lab, we established more
stringent management around toxic chemical

In 2023, all biosafety laboratories enrolled inuse. All scientists are required to wear a video

the Health Authority and obtained P2 permits.

recorder when working with chemicals to avoid

Additionally, we maintained a biosafety program

accidental chemical loss

38 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Guangzhou’s manufacturing
facility celebrated 1,613,858 safe
working hours

Zerofatalities or lost workdays

BioIsland Innovation Center celebrated
175,776 safe working hours

Introduction

Our Approach

Innovating
Sustainably
As a company focused on improving health and increasing
health equity, minimizing our impact on the earth’s life-sustaining
systems is a key aspect of our sustainability commitments. We
particularly recognize our role in addressing climate change, as
the negative impacts of a warming climate correlate to increases

In this chapter,
we share our approach to:2023 Goals & Progressin disease rates, including some forms of cancer, and could

Our Climate Governancedisrupt our operations and delivery of critical therapies for our

Our Climate Strategy

patients. By working to mitigate these impacts and build resilience

Our Climate Risk Management

to future disruptions, we are enhancing our ability to continuallyprovide life-saving medications to people around the world while

Our Climate Metrics

safeguarding our business growth now and into the future.

Climate &Environmental Impact
Product
Stewardship

39 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix2023 Goals & Progress

GOAL
Set a quantitative Scope 1 and 2 emissions
goal by 2024

• On December 18, 2023, together with
our Responsible Business & Sustainability(RB&S) Working Group, we announced
our first quantitative emissions reduction
goal. This newly established target
is to reduce Scope 1 and Scope 2
emissions by 25% per unit of internally
manufactured commercial products by
2026 (with 2021 as a baseline).

GOAL
Develop a global productstewardship program• A gap analysis was launched in the firstquarter of 2024 to develop a formal
product stewardship strategy andstatement. The project will consider
several factors, including opportunities
to minimize the use of resources suchas energy and packaging materials inthe development and distribution of
our medicines and to introduce green
chemistry principles in our production.

GOAL
Set a quantitative Scope 3 emissions
goal by 2025

• We have now completed a Scope 3
global footprint analyses for 2021, 2022,
and 2023. These assessments haveoffered increasingly greater data quality
and completeness and have laid thegroundwork to meaningfully engage
with our most impactful direct suppliersin 2024.

“Reducing our environmental impacts is more important thanever and closely aligned to BeiGene’s focus on improving
human health and the health of the planet. We maintain clear
responsibility for climate-related issues at the Board level and ensure thatclimate risks and opportunities are adequately considered in the company’s
strategic decision-making. This commitment starts at thetop, and we are committed to making Responsible
Business & Sustainably an ongoing priority.”—Alessandro Rivas,
Board of Directors

40 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Our Climate Governance
BeiGene has assigned responsibility for climaterelated issues at the Board level through theBoard’s participation in the Responsible Business& Sustainability (RB&S) Working Group. In early
2023, the working group reviewed and approved
BeiGene’s climate risk assessment and strategy
and, later in the year, approved the first quantitativeemissions Scope 1 and 2 reduction target. Thishas set the tone from the top regarding BeiGene’s
commitment to addressing its impact on theenvironment, as well as the risks and opportunities
the company faces due to climate change.
BeiGene also regularly reviews compliance withcurrent sustainability-related regulations anddisclosure requirements and keeps abreast ofchanging reporting expectations and mandates,
particularly those forthcoming in Europe. A
concise compendium and summary of new andupcoming climate-related regulations focusing on
key markets were shared with the RB&S Working
Group in Q1 2024. We recognize the need for morerobust policies and regulations aimed at reducing
greenhouse gas emissions, water pollution, andother environmental impacts at the local, national,
and international levels, and we view them as anopportunity to strengthen our policies and practices
to further advance our climate-related progress.
For more information on our RB&S Working Group,
please see Responsible Business & Sustainability
Governance, page 51.

41 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Climate Strategy
As the impacts of a changing climate are becoming
more apparent around the world, this global
challenge presents both risks and opportunities
to the success and long-term sustainability ofour business. BeiGene’s plans to build additional
facilities and expand production in the short term
could increase our exposure to climate-related risks
as energy costs rise, carbon pricing is introduced,
and compliance expectations increase, potentiallyputting pressure on our financial standing.
Climate risks may also disrupt our manufacturing,
research and development, and upstream anddownstream activities by increasing raw material
and transportation costs, threatening facilities with

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

To measure and mitigate our climate-related risks

their understanding of climate impacts, incorporatesignificantly mitigate the impacts of climate change

and capitalize on key opportunities to strengthen

their business area expertise into the analysis, andand keep global warming to levels that avoid thethe business, BeiGene has developed a three-phasevalidate the findings. This process determinedmost significant impacts of climate change. In the

climate strategy:

which climate risks or opportunities would be mostsecond “High Carbon” scenario, decarbonizationmaterial to BeiGene over three timeframes: Shortcontinues at its current pace, which is insufficient toUnderstand our baseline impacts and conduct(present–2030), Medium (2030–2040), and Long

avoid the dramatic impacts of climate change.

risk assessments(2040–2050). The assessment also included theIntegrate and operationalize findings to develop

development of two climate scenarios—High Carbon

The results of this assessment identified andmitigation plans at the enterprise leveland Low Carbon—to evaluate risks and opportunities

prioritized the top six risks and opportunities thatSet goals while continuing to ensure alignmentthat could emerge in both. In the “Low Carbon”

BeiGene may navigate in the coming years underwith relevant regulations and the needs of ourscenario, ambitious steps are taken, including policy

each scenario, informing our risk managementbusiness and stakeholders

implementation and technology deployments, thatdecisions and our financial and strategic planning.

1.
2.
3.

Phase 1:Baseline Impacts & Assessment

extreme weather events, and altering the availability

Initiated in 2022, the first phase of this strategy

of biologics critical to anti-cancer drug discovery.

included an inventory of our Scopes 1, 2, and 3
greenhouse gas emissions and a Taskforce on

However, a changing climate also presents

Climate Related Financial Disclosures (TCFD)-

opportunities for BeiGene to build our resiliency andaligned assessment of the climate-related risks

reputation. Over the next few years, the choices weand opportunities across our operations. This

make to address climate challenges could guide theassessment evaluated over 90 BeiGene owned

company’s transition toward more sustainable andand operated offices, warehouses, and production

less expensive energy sources, help us optimize ourfacilities across the globe, utilizing high-resolution

procurement practices and increase supply chain

climate forecasts provided by Jupiter Intelligence.

reliability, and accelerate the transition away from raw

Each asset was rated for its overall exposure to tenmaterials that may become increasingly expensive

acute and chronic climate hazards—including sea

or scarce in a warming climate. Likewise, BeiGene’s

level rise, extreme weather events, and wildfires—

response to these risks could attract new investors

which resulted in exposure scores.

and further our stakeholders’ loyalty and trust while
enhancing our reputation as a company focused on

Surveys, interviews, and workshops were also

becoming a leader in corporate climate citizenship.

conducted with internal stakeholders to further

42 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Risk Exposure (2030)

CriticalTimeframe

Type

Risk/Opportunity

Risk &
Opportunity

Optimize procurement practices for emissions
reduction

Short

Risk &
Opportunity

Expectations and mandates to comply withincreasing climate-related policies

Short

Risk

Attracting & retaining talent throughsustainability commitments and advancementof broader ESG goals

Short

Risk &
Opportunity

Investor & institutional stakeholder
expectations on managing climate-related
impacts

Short

Risk &
Opportunity

Cost of energy sources (fossil fuels)

Short

Risk

Extreme weather impacts (e.g., wind, severe
storms) on production facilities

Short

High Carbon

Low Carbon

MediumHigh

MediumHigh

MediumHigh

MediumMediumHigh

MediumHigh

High

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Phases 2 & 3: Integration,
Mitigation & Goal-Setting

GHG Emissions: 2021 Baseline

The next phases of the strategy implementation

Tonnes of carbon dioxide equivalent (MT CO2e)1

Innovating
Sustainably

OperatingResponsibly

Appendix

Scope 1 & Scope 2 Reduction Strategy

GOAL

include a commitment to establish formal emissions
reduction targets, develop mitigation plans, setgoals, and integrate climate-related risks andopportunities into our Enterprise Risk Management(ERM) process. It also includes identifying changes• Reduce our Scope 1 and 2 emissions
by 25% per unit of internally
manufactured commercial product by
2026 (with 2021 as a base year)

in the regulatory landscape and integrating

TOTAL: 324,097

Scope 3 GHG Emissions Breakdown: 2021 Baseline

those findings into our operational and strategic

To determine an appropriate goal for reducing

planning. In 2023, we launched these integration

Scope 1 and 2 emissions, we engaged in two

and mitigation processes, transitioning strategy

key initiatives in 2023: conducting energy audits

implementation into a cross-functional effort thatat multiple facilities and researching options forbrought teams across the company together to chartincreasing renewable electricity in our energy

a path forward, and began setting our emissions

supply. Based on the detailed data collected,

reduction goals.

we then developed a Scope 1 and 2 emissions

2

Tonnes of carbon dioxide equivalent (MT CO2e)

TOTAL: 285,755
1

Market-based emissions.
The following categories were deemed not applicable to BeiGene: 10. Processing of Sold Products, 11. Use of Sold Products, 13. Downstream Leased Assets, 14. Franchises, and
15. Investments. Category 9. Downstream Transportation & Distribution is deemed de minimis and thus not included. Category 8. Upstream Leased Asset was not included inthis 2021 baseline, as WPS facilities were accounted for under Scope 1 and 2. Going forward, these facilities will be accounted for under Scope 3 as they are leased and BeiGene
does not have direct operational control.

2

reduction target with a high level of confidence
BeiGene is constantly striving to improve the dataand secured executive and Board-level alignment

and methodology we use to calculate our scopedwith our goal through the approval of the RB&S

emissions. Because of this, we have chosen to

Working Group. This climate goal was developed torestate our 2021 Scope 3 emissions as our internal

support our ongoing process to make our operations

improvements surrounding spend data taxonomy

more energy and carbon efficient and to lay the

resulted in more accurate emission factors being

groundwork to ramp up our efforts beyond 2026.

applied to our purchasing categories. This updated

We based our emissions metrics on production

taxonomy was utilized in 2022 and 2023 data,intensity rather than an absolute target to accurately

allowing for a more consistent assessment ofrepresent our emissions-reduction progress as ouremissions by spend category year over year.

business continues its rapid growth trajectory.
Energy Audits & Implementation
To identify the most effective pathways for reducing
energy consumption in our operations, we worked
with an independent consultant to evaluate ourlatest Scope 1 and 2 footprint data and identify which

43 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

facilities generated the highest level of emissions. As

with BeiGene’s significant business growth, we

not all facilities are owned by BeiGene, the selection

developed a strategy that will evolve as ourprocess focused on top-emitting sites most likely tocompany grows and renewable markets mature.

Our Approachremain in our portfolio in the coming years.
To make our facilities more streamlined andThrough these audits, we identified energy efficiency

sustainable as we grow and expand ourand carbon reduction opportunities across four

operational footprint, our team is researchingfacilities and are now in the process of prioritizing

and pursuing options for generating renewableprojects and creating site-specific action plans for

power on-site efficiently and economically. Already

implementation. Most opportunities were focusednearing completion, our flagship U.S. biologics

on optimizing systems, controls, and environmental

manufacturing and R&D facility at the Princeton

settings since three of the facilities are new and notWest Innovation Campus in Hopewell, New Jersey,

yet in need of equipment upgrades. Other projects

has incorporated energy efficiency and renewable

involved installing heat recovery equipment andconcepts in its design and construction, including

replacing inefficient HVAC systems. Identified

accommodations to add a rooftop solar array in themeasures were projected to reduce emissions

future. This new campus will serve as an important

immediately and offer financial benefits in the near

prototype for our on-site renewable energy efforts

term, with an estimated average of two years or lessgoing forward.

return on investment across the sum of all identified
projects.

In parallel with these on-site renewable energy
generation projects, we may also consider

Renewable Energy Projects
In 2023, we conducted extensive research in eachof the markets where BeiGene has a prominent
operational footprint to pinpoint viable options toincrease our allocation of renewable electricity.
This helped us determine the best approach to
implementing renewable electricity strategies
over the short and long term across the company
globally as well as locally. In recognizing the
rapid evolution of renewable technology, paired

purchasing Renewable Energy Certificates (RECs)
to further reduce the impact of our Scope 1 and 2
carbon emissions. Purchasing RECs would allow
BeiGene to claim the environmental benefits ofrenewable power generated offsite, enabling us tomove forward on mitigating our impact in operatingareas, such as China, where the renewable energy
market is still maturing. While we consider this an
option, our primary focus is on energy efficiency andonsite renewable energy projects, which offer thegreatest potential to mitigate our impact.

44 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Scope 3 Reduction Strategy

GOAL
Set a quantitative Scope 3 emissions goal by2025. To advance this goal, engage with top
suppliers most likely to contribute to Scope
3 emissions

Innovating
Sustainably

OperatingResponsibly

Appendix

updated business forecasts and evolving supplierspend to be more strategic with our supplierengagement efforts. Instead, our team identified
the top suppliers most likely to contribute to our
Scope 3 emissions in the coming years and shifted
our engagement focus to this group. This targeted
supplier engagement will further our collaboration
with key suppliers and enable us to collect direct—• Completed Scope 3 global footprint
analysis for 2022 and 2023
• Activating a supplier engagement
program in 2024
In 2021, our baseline year of measurement, our
Scope 3 emissions constituted 88% of our overall
carbon footprint. Although this result fell within
the industry norm, its outsized impact mandated arather than spend-based—data, enhancing theaccuracy of our emissions calculations. As a result,
this data will lead to more effective progress intackling our Scope 3 emissions hotspots, while
also serving as the baseline for setting our Scope
3 reduction goal by 2025. We have identified thefollowing phases for program launch:

the BeiGene procurement team on sustainability

commitment to reducing these emissions. BeiGene

topics, including Greenhouse Gas Accounting,thus established a target in 2022 to set a formal

Target Setting, and Abatement. This phase

Scope 3 emissions reduction goal by 2025 andlaunched in January 2024.

kickstarted initiatives to build climate capacity into
our procurement function, further our engagementwith suppliers, and evaluate potential cost-savings

suppliers and align on how to best engage withrelated to regulations or stakeholder pressure.

setting this goal through our supplier engagement
program. Although we had previously proposed
engaging two-thirds of our top suppliers based on
2021 spend data, we reevaluated this plan based on

Meet one-on-one with category managers toevaluate the status of their relationships withacross the business, while also reducing our risks

In 2023, we continued to make progress toward

Develop webinars and build materials to train

them.


Reach out directly to the top suppliers to holdcollaborative workshops surrounding theirclimate programs and direct emissions datacollection opportunities.

Introduction

Our Climate Risk
Management

AdvancingGlobal Health

Our Approach

Innovating
Sustainably

OperatingResponsibly

Appendix

our operations and practices and furthering ourcontingency planning to build our resilience
to identified climate risks. See Enterprise Risk

Unmitigated Financial Risk or Opportunity (2030)

Management, page 53, for more information on
In 2022, we engaged internal stakeholders to

Empowering
Our Colleagues

our ERM process.
Predicting the financial impact of climate risks isand opportunities at BeiGene. Following thiscomplicated due to the interconnected nature ofgroundwork, we began collaborating with ourthese challenges within the business and a lack ofEnterprise Risk Management (ERM) team to integratequantified public projections of transition climate

the climate-related risks and opportunities into therisks along climate scenarios. Likewise, theexisting risk processes and governance structure.

potential positive impact of careful contingency

The overarching enterprise risk, “Climate Risk andplanning is difficult to predict. As part of our

Disclosure,” was added to the risk register, housing

climate risk assessment, we identified financial

the top six climate-related risks and opportunities

trends that may occur in each climate scenario,

identified in the 2022 climate risk assessment as

which will enable us to better understand andsub-risks. As a part of this process, individual climate

communicate potential impacts on our businessrisk owners were identified for each of the sub-revenue (see Unmitigated Financial Risk orrisks to secure buy-in on the risk mitigation plan

Opportunity chart). We will continue to collecttemplate, develop mitigation activities, timelines,

the data needed to further refine these financial

and budget allocations, and to enable the creation

projections to better inform our planning andof an integrated risk overview for our enterprise.

decision making regarding our climate-related

The process is informing our strategy for adapting

efforts.

Optimize
Procurement PracticeSustainability
Talent Attraction

Mandates & Expectations
from Policy*

Cost of Energy
Sources

Extreme Weather
EventsDecreased Risk

to determine the top six climate-related risks

Increased Risk

collect asset-related data and insurance information

Low Carbon
High Carbon*No impact

45 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Our Climate Metrics
To deliver on our mission of bringing cutting-edge
medication to patients around the world, BeiGene

GHG Emissions

Although the progress over this last year indicates that we have

has continued to expand our global operations andIn 2023, BeiGene’s Scope 3 emissions accounted for almost 86% of ouralready achieved our 2026 Scope 1 and 2 reduction goal, the 25%

production capacity over the past year. Between

total emissions, followed by Scope 2 at 14% and Scope 1 at less than 1%.

reduction target took into account BeiGene’s business plans (and future2022 and 2023, our product volume increased

expansions) over the next several years, which could trigger increases

94%, with Guangzhou manufacturing’s production

Although BeiGene’s Scope 1 and 2 GHG emissions increased by 38%

in these emissions as new facilities come online. We will continue toof tislelizumab increasing 117% and Suzhou

in 2023 over 2022 levels, the overall GHG emissions intensity per

focus on driving energy and carbon efficiencies across all existing andManufacturing’s production of BRUKINSA andkilogram of internally manufactured commercial product decreased by

new facilities to remain on track and solidify our achievement of thispamiparib increasing 33%.

32% compared to our 2021 baseline due to the increase in production

target by 2026.

volume. In the Guangzhou manufacturing facility, in particular, despite a
To uphold our commitment to innovating

30% growth in Scope 1 and 2 emissions, significant production increases

Compared to 2022, BeiGene’s Scope 3 emissions increased by 120% insustainably, we are continuing to refine ourresulted in a 40% decrease in Guangzhou’s emissions intensity. Likewise,

2023, primarily due to a 79% growth-driven increase in spending in theoperations in order to continue this business

BeiGene’s Suzhou facility experienced a 23% decrease in emission

Purchased Goods and Services category—which accounts for

growth responsibly. In 2023, initiatives to reduce

intensity despite a 3% increase in emissions.

70% of our 2023 Scope 3 emissions.

our emissions, energy use, water use, and waste
production per kg of commercial product met
GHG Emissions (tonnes CO2e)1

with further success, as shown in the

Scope 1 and 2 GHG emissions per kg of commercial product(tonnes CO2e)3accompanying charts.
As a rapidly growing company, we recognize

Value chain
emissions (Scope 3)that our sustainability progress will differ fromyear to year, as we add facilities and continue toIndirect GHG
emissions (Scope 2)2

ramp up production. Thus, our ability to track andDirect GHG
emissions (Scope 1)

make progress on these fronts will rely on robust
data. As our capabilities and access to data
increase each year (particularly supplier-baseddata), we will continue to improve our methodology
and accuracy in data collection and analysis,
further enhancing our sustainability progress.

1
2
3

46 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Due to rounding, numbers may not sum to total
Scope 2 emissions are market-based emissions.
Commercial product refers to net weight of commercial products, not including packaging.

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Energy Consumption & Intensity

Water Consumption

Waste

In 2023, BeiGene’s total energy consumption increased

In 2023, our company-wide water consumption

In 2023, BeiGene generated a total of 1,393 tonnes of waste, roughly

by 31%. However, when evaluated against the increase inintensity decreased by 50%, due to our water use

an even split between hazardous and non-hazardous. Althoughproduction volume, our energy intensity decreased overall

remaining largely consistent with 2022 level despite

the total volume of waste generated increased by 33% comparedby 33%. Our reduction in natural gas consumption was aour increase in production volume.

to 2022, our waste intensity also decreased by 31%. The increasesignificant contributor to this decrease in energy intensity.

in non-hazardous waste production was driven by newly added
facilities and overall usage.

Total Energy Consumption (MWh)Total Water Consumption (cubic meters)1

Total energy consumption per kg of commercial product(MWh/kg commercial product)2

Total water consumption per kg of commercial product(cubic meters/kg commercial product)2

1 Global office data was excluded from these metrics.
2 Commercial product refers to net weight of commercial products, not including packaging.

47 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Waste (tonnes)1

Hazardous waste per kg ofcommercial product(cubic meters/kg commercial product)2

Non-hazardous waste per kg ofcommercial product(cubic meters/kg commercial product)2

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Our Operational Footprint
BeiGene has multiple R&D facilities and manufacturing facilities and maintains offices in several geographies to facilitate clinical
trials and applications for approvals and reimbursements. Facilities currently in its portfolio include:

Beijing R&D

Suzhou Manufacturing

Over 19,800 m R&D facility; a pilot scale

A 13,000 m2 site, which includes over(approximately 140 m2) manufacturing site

8,000 m2 of small molecule production

for preclinical and clinical trial materials forcapacity. Construction is underway on asmall-molecule drug candidates; and a

new 50,000 m2 campus that is expected

38,000 m2 research building under construction,

to eventually expand small molecule

expected to open in 2025

manufacturing capacity to one billion

2tablets/capsules annually, which is ten

Shanghai R&D

times more than its previous capacity.

Over 13,000 m facility with a recently

Phase 1 of the construction project was

opened 2,375 m research spacecompleted in Q4 of 2023, which expanded22production to 600 million tablets/capsules

Taipei R&D

annually. The facility also produces candidates

3,270 m facility

for clinical supply with a 2 x 500-liter capacity

2

Hopewell Manufacturing
Guangzhou BIC

A 37,160 m2 commercial-stage manufacturing

41,000 m2 BioIsland incubator for new

and clinical R&D campus that is currently underbiotechnology businesses

construction and expected to open in thesummer of 2024

Guangzhou Manufacturing
Approximately 158,000 m2 state-of-the-art,commercial-scale facility for the manufacturingof large-molecule biologics, with an approved
24,000-liter capacity for commercial production

48 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

OperatingResponsibly
Grounded in our mission and exemplified in our values, BeiGene
works to build trusted relationships with all our stakeholders sothat we can best support their needs as our business evolves andgrows. We are committed to conducting our business activities
with honesty, integrity, and transparency—a commitment thatIn this chapter,
we share our approach to:
Corporate Governancebegins with our Board of Directors and extends to our colleagues,

Enterprise Risk Managementbusiness partners, and suppliers.

Our Policies
Product Quality Control Systems
Transparency Commitments
Responsible Procurement

49 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

Corporate Governancerecommendations on changes to the Board of
Directors. In reviewing the Board composition, ourBoard Structure

Good governance is fundamental to the long-term

Nominating and Corporate Governance Committee

Committee Composition

success of our business. Our governance structure,

considers, among other characteristics, thepolicies, and commitments are designed to addressnationality, ethnicity, gender, age, skills, expertise,

the needs of our company, stakeholders, andand industry and regional experience of directors

patients and promote a responsible, transparent

and nominees. Our Board is comprised of elevenculture across each of our functions, regardless of

directors, two of whom are female.

Name

Independent
Director

John V. Oyler 

global location. They also highlight our leadershipand Board’s commitment to our values and mission.
Our Board of Directors guides our business

Recent Changes in Board
Composition

Xiaodong Wang, Ph.D.

Olivier Brandicourt, M.D.

I

Margaret Han Dugan, M.D.

I

Donald W. Glazer

I

Michael Goller

I

Anthony Hooper

I

Ranjeev Krishana

I

Alessandro Riva, M.D.

I

goal-setting.

Corazon (Corsee) D. Sanders, Ph.D.

I

BeiGene maintains a Board Diversity Policy to

Quingqing Yi

strategy and ensures we have strong leadership

In January 2024, BeiGene announced theand appropriate oversight across our operations.

resignation of Thomas Malley from the Board andApproximately 80% of the Board is independent,

the appointment of Olivier Brandicourt, MD. Dr.

as determined in accordance with the rules of theBrandicourt brings over 30 years of experience

NASDAQ Stock Market and HKEX. The Board isin the global pharmaceutical industry, including

comprised of five independent board committees:

expertise in leading multinational growth companies(1) Audit Committee, (2) Compensation Committee,

during his tenures as CEO of Sanofi S.A. and Bayer(3) Nominating and Corporate Governance

HealthCare AG. He is currently a Senior Advisor at

Committee, (4) Scientific Advisory Committee,

Blackstone Life Sciences and a director of Alnylamand (5) Commercial and Medical Affairs Advisory

Pharmaceuticals, Inc., BenevolentAI S.A., andCommittee. Four members of the Board also sit on

Dewpoint Therapeutics, Inc. He also serves as chair

the cross-functional RB&S Working Group, whichof the board of AvenCell Therapeutics, Inc. For more

provides oversight for RB&S strategy, progress, anddetails, please see our latest Proxy Statement.

enhance the diversity of our Board membership.
Pursuant to the Board Diversity Policy, ourNominating and Corporate Governance Committee
annually reviews the structure, size, and compositionof the Board and, where appropriate, makes

50 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTI = Independent Director

 = Chairman of the Board= Chairperson= Member

Audit
Committee

Commercialand Medical
Affairs Advisory
Committee

OperatingResponsibly

Compensation
Committee

Nominating
and Corporate
GovernanceCommittee

Appendix

Scientific
Advisory
Committee

Introduction

Executive Leadership Team

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

drive our innovation and expansion as a company.

Within BeiGene, the Responsible Business &input from multiple disciplines, the company

Our expansive Executive Leadership team serves

We are committed to diversity in leadership, andSustainability function is led by our Executive

assembles cross-functional working groups.

as the key connector across corporate functions,currently, women represent approximately 30% of

Director of Responsible Business & Sustainability,

Recommendations from each working group aretying our processes to purpose and guiding ourour Executive Committee.

who works cross-functionally to identify

approved by functional leads and members of theopportunities for improvement and to further

broader executive team, before eventual approval

integrate BeiGene’s RB&S strategy in eachby the Board.

work to make the greatest impact while furthering
our stakeholder interests and company mission. Our
co-founders, John V. Oyler, CEO & Chairman of theBoard, and Xiaodong Wang, PhD, Chairman of the

Responsible Business &Sustainability Governance

Board Scientific Advisory Committee, have built a

As part of its normal course of business, the Board

substantial team of individuals across five continents

regularly participates in discussions on specificto lead our work.

responsible business issues core to our businessstrategy, including efforts to expand access to our

The Corporate Planning Team sits at the top of

medicines and employee engagement activities.

our executive leadership structure and includes

The Board also reviews progress against our broader

our Chief Executive Officer, Chief Financial Officer,

strategy and goals at least annually, in addition to

Chief Operating Officer, General Counsel, Head

its review of our annual Responsible Business &of Research & Development, Head of Human

Sustainability Report.

Resources, Head of Strategy & Corporate
Development, and the Strategic Advisor and Special

Given the increasing importance of responsible

Assistant to the CEO.

business and sustainability issues to both ourcompany and external stakeholders, we establishedThe broader Executive Leadership Team, also

a dedicated RB&S Working Group. The working

known as our Executive Committee, is spread acrossgroup is comprised of four Board members and 11

six areas of the business: Corporate, Functional

colleagues from different functions, including two

Leads, R&D, Commercial & Medical Affairs, Technicalmembers of the Executive Committee. The working

Operations & Supply Chain, and Corporate Affairs.

group meets quarterly with BeiGene’s Responsible

As a global company looking to make a substantial

Business & Sustainability team to review pressing

impact in health equity and access to cancer

topics and emerging issues. In early 2023, thetreatments, we have been able to attract strong

working group reviewed and approved BeiGene’s

candidates at the top of their fields. Nearly 50%

climate risk assessment and strategy and, later inof this leadership team holds a PhD, MD, or both.

the year, approved the first quantitative emissions

Their talent and depth of experience have helped

reduction target.

51 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

department. For longer-term projects that require

Responsible Business & Sustainability Oversight
Board of Directors
Responsible Business & Sustainability Working Group
Christine Riley Miller
Executive Director, Responsible Business & Sustainability
Ranjeev Krishana
Lead Independent Director

Corazon (Corsee) Sanders
Independent Director

Alessandro Riva
Independent Director

Anthony Hooper
Independent Director

Chan Lee
General Counsel & Corporate Secretary

Qing Nian
Assistant General Counsel

Michael Schoen
Strategic Advisor and Special Assistant to the CEO

Yan QiHead of Public Affairs, China

Beth Wensley
SVP, Head of Portfolio and Program Management

Chris Palermo
VP, Internal Audit

Michon Pinnix
VP, Corporate Development

Elaine Samuels
Associate Director, Communications, Europe

Lauren Ayala
Director, Responsible Business & Sustainability

Executive Sponsor

Shreya Jani
Senior Vice President, Corporate Affairs

Introduction

Our Approach

Succession Planning

Stakeholder Engagement

As BeiGene has matured and expanded over the

To ensure we deliver on our mission to build a next-

last several years, we have focused on building ourgeneration global oncology company, we need toteams to meet increasing demands and prepare

understand the needs of our many stakeholders.
Across the organization, our colleagues are

our executive leadership team received successioninteracting with and learning from various

planning training. Board oversight on executive

constituencies that have a vested interest in how wesuccession planning is handled by our Nominating

manage our business. Individual functions leverage

and Corporate Governance Committee.

insights from these interactions when creating their

Empowering
Our Colleagues

Innovating
Sustainably

to responsible business goals and program

formalize Individual Development Plans (IDPs)

development. Our biennial engagement surveys

focused on preparing our future leaders toand pulse surveys also serve as opportunities forstep into new roles when needed. In 2023, we

our colleagues to engage and offer feedback to

officially launched Leading Innovation and Future

leadership.

Key Methods of Engagment

Desired Outcomes

Our Patients,
Caregivers &Healthcare
Providers• Educational content, including videos, forums, and webinars• Fact sheets• Meetings• Newsletters• Website and online channels• BeiGene’s “Talk About It” Program• Patient Advisory Boards• Key learnings regarding challenges for each patient population• Benefits our therapies may provide for patients, caregivers, andhealthcare providers• Innovation and collaboration on future treatments• Trust• Advocacy conferences• Charitable contributions, sponsorships, and medical education
grants• Forums and advisory groups• Meetings• Patient insights into drug development• Website and online channels• Support, education, and resources provided to patients• Better understanding of the unmet needs of our patients• Prioritization of our patients’ needs in order to improve
oncology-related policies• Incorporation of the patient voice into our R&D efforts• Expanded advocacy for PAOs’ diverse populations to improvehealthcare access• Patient transparency• Company town halls and events• Coffee and Conversations• Surveys• Workshops and professional development courses• Inclusion, Diversity, Equity, and Awareness (IDEA) Council• Compliance/Whistleblower Helpline• Performance reviews and management• Retention of key talent• Employee engagement• Employee education and development• Recruitment of diverse and high-quality candidates• Employee satisfaction• Supplier Enablement Help Desk
• Online Supplier Network• Webinars• Workshops and meetings• Innovation and collaboration• Transparency• Risk mitigation for variables such as extreme weather,geopolitical issues, or supply shortages• Achievement of shared goals, such as environmental
sustainability

Industry Groups& Professional
Societies• Industry conferences• Industry association meetings• Medical education• Professional networks• Innovation through the sharing of challenges and best practices• Education and awareness of emerging trends

Academic
Institutions• Medical & academic conferences• Relationships with academic medical centers• Professional networks• Innovation and collaboration• Educational opportunities

Investment
Community• Annual Reports and Proxy Statements• Investor conferences• Medical meetings• Meetings/Events• Other SEC filings• Press releases and corporate updates• Website and online channels• Access to management• Education• Transparency

Government
Policymakers &Elected Officials• Compliance program• Quarterly disclosure report• Engagement with industry trade associations and coalitions• Education of policymakers and legislators• Improvement of public policies for patients and innovators

Local Communities• Employee volunteerism• Employee charitable giving• Community support• Employee engagement and satisfaction• Support and resources for local businesses and community
organizations

Patient Advocacy
Organizations

Colleagues

Transformation (LIFT), our global, cross-regional,

Suppliers

and cross-functional senior leadership program.

Externally, BeiGene participates in numerous

Additional details about our executive succession

industry associations and professional networks

efforts are highlighted in Empowering Our

relevant to our business. Participation in theseColleagues, page 27.

organizations allows us to exchange information,offer and learn from best practices, and actively
participate in the betterment of the industry.
To read about additional stakeholder engagement
processes, see Patient Engagement, page 18,
Patient Advocacy, page 25, and Responsible
Procurement, page 59.

8

52 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTAppendix

Stakeholder

departmental strategic plans and when contributing
We are currently working with select talent toOperatingResponsibly

Stakeholder Engagement8

for our future. In 2022, BeiGene developed a global
leadership succession plan, and all members of

AdvancingGlobal Health

Our interactions with stakeholders are subject to local laws, regulations, and industry codes.

Introduction

Enterprise Risk
Management

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

The ERM Executive Committee meets quarterly—
or more frequently if necessary—and validates
mitigation plans and activities. The ERM lead reports
to the Audit Committee of the Board quarterly

BeiGene is deeply committed to our Enterprisewith updates on issue progress and reports to the

Risk Management (ERM) practice and further

Executive Committee periodically as well.

development of our risk planning, including
the dedicated oversight of risk assessment,

In 2023, when the ERM team reassessed priority risk

management, and mitigation by our Head of ERM.

areas, they determined that additional risks needed
to take precedence due to the company’s expansion

Starting in 2021, BeiGene committed to ourand development. In prioritizing the risk associatedgeneral ERM methodology, which includes a risk

with climate change, the ERM team worked withassessment approximately every two years. Our

the Responsible Business & Sustainability team torisk assessment methodology includes the input of

integrate climate risk into the enterprise-level riskorganization leaders and subject matter experts tomanagement program. Additional details about ouridentify new and ongoing areas susceptible to risk.

integration of climate and business risks can beOnce identified, risks are weighed against impact,

found in Climate Risk Management on page 45.

likelihood, and vulnerability and scored to create
our risk inventory. We then develop an engagement

Our ERM program helps BeiGene mitigate andplan to address each of these risks and the process

prevent corporate risk as well as foster collaboration

for monitoring and mitigation follow-through.

across functions to address issues proactively and

Additionally, as risks emerge or are identified during

comprehensively.

the cycle and between formal assessments, we
perform individual assessments and develop andexecute mitigation plans.
Each risk has an executive sponsor responsible
for overseeing the engagement plan process and

For rapidly growing companies, it can be hard to see risks
across functions. Yet very few things happen in isolation, andhandling risks on a siloed basis is not efficient for a global
company. The expansion of our Enterprise Risk Management program
have been significant for BeiGene in that it allows us to bring together
teams globally and across functions to address risks holistically. It’s
been encouraging to see our teams recognize and take an active roleas risk owners and work creatively to address them.
The continued growth of our program speaks to ourvalues as well—Bold Ingenuity in the face of risk anda Collaborative Spirit as we work toward solutions.

functional risk owners who address individual
aspects of mitigation. The core ERM team meets on
a weekly basis and connects with each risk owner at
an established cadence to ensure mitigation plans
are on track, with flexibility as needed, if issues arise.

53 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT—Marc Polk
Head of Litigation and Enterprise Risk Management

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Our Policies

In addition to Code of Conduct training, BeiGene

Committee of our Board of Directors receives

implemented tailored trainings throughout 2023

quarterly reports on anti-corruption and significant

At BeiGene, we are committed to ensuring ethicalon key topics, including our Insider Trading Policy,

compliance program activities.

work in all aspects of our business. Earning the

updates to our Global Healthcare Compliancetrust of our stakeholders by putting patients at

Manual, and our Privacy Policy. We also launched athe forefront, conducting business responsibly,compliance culture campaign globally to promoteand being open and transparent starts with oura culture of ethics and integrity. The campaign

policies and procedures. We adopt industry-leading

included the creation of a compliance champion

We promote an open-door policy and encourage

standards, partner with organizations that share our

network, which highlighted compliance interests

our colleagues to ask questions or raise concerns

values, and support healthcare industry efforts andfrom the top down, quarterly newsletters on

without hesitation or fear of retaliation. If individuals

government policies that advance science, enhancecompliance topics and expectations, as well as

are not comfortable reporting issues of concern

medical innovation, and work to build health equity

leadership quote cards and video clips. In China,

directly to management, they may file anonymousfor patients around the world.

we also hosted our first Compliance Day for ourcomplaints via our compliance hotline or web

colleagues on September 22, 2023, to reinforce ourportal, available 24 hours a day, 365 days a year, in

commitment to a compliance culture.

multiple languages. BeiGene prohibits retaliation,

Business Ethics
Our Code of Conduct guides our daily interactions
with one another and with our stakeholders—from

Whistleblower & Anti-Retaliation
Protection

who files a complaint, assists with or participates in
an investigation, opposes harassment, or otherwise

our patients and their doctors to government

BeiGene takes a zero-tolerance approach toregulators and our collaboration partners. We

bribery and corruption and is committed to acting

pursue our business objectives with integrity andprofessionally, fairly, and with integrity in all our

Avenues for raising complaints are discussed duringrespect and in compliance with applicable laws andbusiness dealings and relationships. We assign a

new hire and other ethics trainings as well as in our

regulations. Our Code of Conduct addresses issues,

combination of electronic learning modules andCode of Conduct and Harassment, Discrimination,

including compliance, interactions with healthcare

live trainings on our Anti-Bribery and Corruption

and Retaliation Policy. BeiGene also has a formalized

professionals, anti-competitive behavior, conflicts

Policy and related topics to all colleagues. Global

Reporting Misconduct Policy. All reports areof interest, confidentiality, and more. We continuallye-learning modules are incorporated into an annual

investigated thoroughly and independently bypromote a culture of integrity and ethical operations

curriculum at least every other year. Live training

designated legal, compliance, or human resources

through new hires and regular trainings and maintaincourses are conducted based on an employee’s

personnel, and appropriate disciplinary or preventive

robust monitoring and reporting systems. Each year,role within the organization. For sales personnel, foractions are taken to address any findings according

colleagues are asked to certify that they understandinstance, we have separate ethical marketing training

to BeiGene’s Compliance Investigations andand will comply with our Code of Conduct. Codeprograms—including live and virtual sessions, FAQs,

Corrective Actions Standard Operating Procedure.

of Conduct training and certification was last

and tests—to ensure they understand relevant

Significant investigation matters are reported to thecompleted in Q4 2023.

policies and regulations. Additionally, the Audit

Audit Committee quarterly.

54 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

OperatingResponsibly

Appendix

Animal Welfare
In the development of new and innovative
medications, occasionally the use of purpose-bredanimals is required. BeiGene is committed to theharassment, or other adverse action against someone

Anti-Bribery & Corruption

Innovating
Sustainably

exercises rights protected by applicable laws.

humane and ethical treatment of animals utilized inresearch and has policies and procedures in place
to ensure these standards are maintained. This
includes a rigorous study design process to ensurethat the animals used in research are absolutely
necessary.
We follow the 3R (replace, refine, reduce) principles
set by the National Research Council and are
guided by our Animal Welfare Statement, which
underscores our commitment to ensuring the ethicaltreatment of animals in all parts of the business.
Our robust efforts in this area were validated uponreceiving accreditation with the Association for
Assessment and Accreditation of Laboratory Animal
Care International (AAALAC International) in 2023.
For more information about our commitment to thehumane and ethical treatment of animals, pleasesee our Global Statement on Animal Welfare.

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Data Privacy & Cybersecurity
BeiGene is committed to protecting our patients’BeiGene is currently ISO 27001: Information Security

Each year, privacy and data security trainings are

Functional privacy training is also provided to criticaland our company’s data. We strive to mitigate

Management certified, which is renewed every

conducted as part of the standard new employee

departments to ensure that our colleagues are

privacy and cybersecurity risks and increase visibility

three years with yearly incremental external audits.

training curriculum globally and is required of all

trained and aware of function-specific needs.

and awareness throughout our company. Each of

As a part of ISO 27001, we have a comprehensive

existing colleagues to complete annually.

BeiGene’s functions is responsible for its compliancesuite of information security policies that governwith data privacy laws and regulations, with support

our Information Security Program and drive thefrom and in alignment with policies issued by

mitigation of security risks within the Company.

the BeiGene Privacy Office and the Information

In addition to ISO 27001, our Information Security

Governance Team, which are part of the Legal andProgram aligns with the National Institute ofCompliance Department, as well as the Information

Standards and Technology Cybersecurity

Security Team, which is part of Global Technology

Framework, which is assessed yearly. These controls

Solutions.

include a Data Breach Policy and an Information
Security Incident Response Plan.

BeiGene mandates that only the minimum amountof personal data should be collected for its intended

To further integrate and educate colleagues about

purpose and should be deleted or returned when it

cybersecurity, the BeiGene Global Technology

is no longer needed or required by law to be stored

Solutions team hosts an annual Cybersecurityby the company. Where required by applicable data

Awareness Month with on-site and online

protection law(s), BeiGene provides data subjects

workshops. From mid-October to early-November

As the Privacy Office seeks to further connect BeiGene’s privacy efforts to our Responsible Businesswith the required individual rights with respect to2023, colleagues were able to attend trainings& Sustainability practices, they partnered with the PICCASO Privacy Lab and a select number of

their personal data. To manage and document what

to stay up to date on the latest security threats,

multinational corporations to develop a whitepaper examining the connection between privacy

personal data is collected and how it is processed,

best practices, and strategies for digital safety in

and RB&S principles. The paper, published in October 2023,

BeiGene has implemented a data governanceour ever-evolving world. In 2023, Cybersecurity

illustrates how privacy compliance can potentially enhance ansystem that ensures appropriate controls are in

Awareness Month included ten in-person andorganization’s RB&S rating and provides practical guidance onplace governing the collection, use, storage, andfive virtual workshops, engaging approximately

how to effectively report on privacy and data protection in thedeletion of personal data. The system integrates

3,200 participants globally. Additionally, BeiGene

context of RB&S.

a centralized process to receive and address

recognizes an annual Privacy Day in January, andindividual rights requests in a timely manner. As acirculates a quarterly privacy newsletter to all

Moving forward, the Privacy Office will continue to proactively

result, patients and customers can be confident that

BeiGene colleagues to foster a stronger privacy

address privacy efforts throughout the organization and takethe company knows where and why their personal

culture and raise awareness of privacy work within

steps to encourage a stronger privacy culture.

data is being processed and that their rights are

the organization.

respected and upheld.

55 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Connecting the Dots Between Privacy andResponsible Business & Sustainability Practices

GOAL• Develop a plan to betteralign key privacy performance
metrics with Responsible
Business & Sustainability
practices by 2025

Introduction

Product Quality
Control Systems

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

culture of quality in our business processes andprinciples as needed to maintain an effective quality

functionally to develop and implement solutions

for our people, and support our compliance withsystem. We leverage advanced quality metrics todesigned to mitigate risks associated withapplicable laws, regulations, and internationally

easily review data on a site-by-site level to identify

counterfeiting, diversion, theft, and illegal resale ofrecognized standards. Our internal standards may

strengths and areas for improvement. Our QMS is

our medicines.

At BeiGene, we are committed to conducting our

be stricter than those required by national andbroad and encompasses critical processes suchresearch studies and clinical trials responsibly andindustry practice and are optimized and enhanced

as change control, deviation management, andWhile no counterfeit BeiGene medicines have

ethically. Our bioethics program, based on the coreon an ongoing basis. We expect our subsidiaries

complaint monitoring.

been identified to date, in the cases where BeiGene

values of respect for autonomy, non-maleficence,and external business partners, such as vendors,

beneficence, and justice, provides a framework tocontract manufacturers, contract research

Our Quality Compliance auditing program

our Global Brand Protection’s investigative and law

guide internal decision-making, helping us deliverorganizations, specialty service providers, contract

continuously samples QMS performance at sites,

enforcement referral program was able to addresson our mission with integrity.

colleagues, and distributors, to demonstrate theircontractors, and suppliers and provides an early

the issue and reclaim the illegally diverted medicines.

alignment with our quality requirements to achievewarning system for any performance issues acrossBased on growing concerns regarding industry data

patient safety and compliance.

our network. Our risk management program

showing significant increases in counterfeiting ofcontribute to our R&D efforts receive training

ensures that we focus on the highest priorities insolid dose and injectable forms of cancer medicines

annually (or as revised) on SOPs and guidelines

line with ICH Q9.

worldwide, BeiGene’s Brand Protection Working

All BeiGene colleagues and outside vendors thaton bioethics issues established by the World

Quality Management Systems

detected illegal diversion of our medicines in 2023,

Group, consisting of global representatives from

Medical Association Declaration of Helsinki,

BeiGene operates a comprehensive Quality

In October 2023, we announced a comprehensive

Legal, Global Supply Chain, Quality Assurance, Global

guidelines established by the International Council

Management System (QMS) in line with structures

restructuring of BeiGene’s Quality team, which

Patient Safety, and ten other BeiGene departments,for Harmonization of Technical Requirements forsuch as ICH Q10 and E6 and complies with all GxP

became effective in Q1 of 2024. This restructuring

convened in April 2023 to discuss the progress of

Pharmaceuticals for Human Use (ICH), and the BIO

regulations for all jurisdictions to which we supply

has prepared BeiGene for the next decade, bringing

current efforts and identify additional protections toStatement of Ethical Principles. We also employ

products. The system covers the full productthe organization in line with our business andmitigate threats to our patients.

safeguards to protect patient privacy that is guided

development cycle and incorporates requirements

geographical structure to create cross-functional

by our global Privacy Policy, which establishes coreof Good Laboratory Practice (GLP), Good Clinicalteams focused on each aspect of quality and

BeiGene already employs product traceability byrequirements for the use, storage, and transmission

Practice (GCP), Good Pharmacovigilance Practiceensure best practices and compliance continue toallocating unique identifiers (UID) to each packageof medical and genetic patient data.

(GVP), Good Manufacturing Practices (GMP), andbe met.

of medicine. This UID is created and stored in a

Good Distribution Practices (GDP).

Quality Assurance

In addition, we have set up comprehensive,

database for traceability purposes and can beProtecting Against Counterfeit& Illicit Medicines

used to track and trace any product throughout
the BeiGene supply chain. Additionally, BeiGene

Our commitment to quality and safety extends

risk-based monitoring programs to ensure theacross our business, from R&D to the distribution

robustness and effectiveness of our quality system.

BeiGene is committed to combating counterfeit

technologies to further protect our medicines andof our medicines. We have developed a

We carry out Quarterly Management Reviews of the

medicines that could jeopardize patient healthpatients. This technology will enhance existing

comprehensive, robust quality assurance andperformance of our Quality System and implement

and safety. Our Brand Protection function within

on-package features and help identify counterfeit

control program to generate awareness, foster aenhancements based on operational excellence

our Global Security department works cross-

medicines within the supply chain. In 2024, the56 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

has evaluated multiple brand protection packaging

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

working group plans to test the technologies toensure effectiveness prior to further expansion.
BeiGene has continued efforts to improve incident
reporting and ensure supply chain security
standardization with our business partners, including
the incorporation of contractual agreements
relating to product integrity and cargo security.
New and active brand protection initiatives resulting
from cross-functional discussions include pilot
investigative programs relating to regional diversion
schemes, trademark recordation at global customs
agencies to increase the likelihood of unapproved
medicine seizures at border crossings, and the
addition of regional BeiGene Brand Protection
professionals to cover Europe, Middle East, Africa,and Latin America.
Because the focus of BeiGene’s Brand Protection
program is to protect patients, the working groupalso created an informational webpage, AntiCounterfeiting and Brand Protection. The webpage
provides patients with a variety of information,
including the program’s mission, an updated listof global program objectives, and methods forpatients to report serious incidents to BeiGene andhealthcare agencies.

57 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Innovating
Sustainably

OperatingResponsibly

Appendix

Bioethics
BeiGene’s research team deploys several
investigative techniques in our quest to develop new
therapies. For example, we use genetic engineering
tools, including polymerase chain reaction (PCR),transformation/transduction, and clustered regularlyinterspaced short palindromic repeats (CRISPR)
routinely in our research efforts. These tools
enable us to perform gene mutation, insertion, andknockout in cells. Researchers conducting thesestudies receive training on appropriate regulatory
requirements, protocols, and expectations for
documenting outcomes.
As new technologies emerge, we remain committed
to assessing the safety of the technology andengaging with appropriate external stakeholders to
mitigate potential risks.

Introduction

Transparency
Commitments

Our Approach

medicines may only be promoted for their approved
indications and for use in accordance with theprovisions of the approved label. We have separate
ethical marketing training programs for sales

At BeiGene, we seek to provide our patients,

personnel to ensure they understand all relevant

healthcare providers, and regulators with thepolicies and regulations.

information they need to make informed choices
regarding our medicines. We strive to be forthrightand transparent in our interactions with all
stakeholders.

Government Policy Advocacy
BeiGene regularly engages with government
policymakers and elected officials on issues

Responsible Marketing

regarding our mission to provide high-quality,
affordable medicines to patients. We comply with

As part of our commitment to transparency,

international governance guidelines and country-

we employ stringent procedures to ensure our

specific regulations and laws, such as the Lobbying

marketing communications are truthful, accurate,

Disclosure Act in the U.S., and individual stateand provide important contextual information that

requirements to ensure appropriate interactions

will assist healthcare providers in determining

with government officials. In the U.S., our quarterly

whether our medicines are appropriate for a patient

disclosure reports are public and can be foundand in understanding potential side effects.

at the U.S. House of Representatives lobbying
disclosure website and the U.S. Senate public

Our responsibility begins with developing accurate

disclosure website.

labels for our medicines. Our Executive Labeling
Committee reviews all new labels or significant
labeling changes before their submission to aregulatory agency and/or before a product isreleased for commercialization. Additionally, our
Promotional Review Committee ensures that all
external promotional messages and claims are
consistent with the approved label and indicationin each market. This Committee also reviews
messages to ensure they are medically accurate andmeet local regulatory and legal requirements. Our

58 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Responsible
Procurement
BeiGene understands the importance of working

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

service agreements, globally and regionally, containof any behaviors or conditions not in complianceassessment levels based on the risks suppliers may

language requiring supplier compliance with thewith our standards, we take immediate action topose to the company and their spend category andCode. This includes all new contracts, purchasecommunicate these issues, work with our suppliers

criticality.

orders, and proposals.

to develop a mitigation plan, and take remedialwith suppliers that share our commitment to high-action steps to return to compliance.

Additionally, as part of our environmental

quality products and responsible operations. Our

All members of the Global Procurement Team

global procurement team has evolved in the lastreceive corporate and locally tailored trainings

In the summer of 2022, we hired a manager tocommitments, BeiGene has developed aquestionnaire to gather information regarding

year to focus on third-party risk management andon our procurement policies and approach. We

oversee the implementation of a new third-party

supplier’s processes and climate-related data

the launch of our supplier engagement program,also offer additional optional trainings for our

supplier risk management program, which camecollection activities. BeiGene is working to collectas well as our ongoing efforts to ensure the safety

team members to improve responsible business

into force in 2023. Through this program, BeiGene

this information from our key suppliers and will be

and quality of the materials we buy. We lay out

and sustainability practices in our supply chain,

has started screening all new vendors to ensure that

establishing a cross-functional process to manage

our expectations in our global Supplier Code offrom evaluating supply chain risks to improving

proposed suppliers meet expectations surrounding

any identified climate risks.

Conduct and monitor performance through multiple

supplier diversity, among others. Additionally,

proof of incorporation or business operations andchannels, including new vendor screening, ourBeiGene became part of Procurement Leaders,

are not subject to trade restrictions or sanctions. The

supplier due diligence program, and our new third-

an organization dedicated to helping procurement

new third-party supplier risk management program

party risk management program.

professionals make faster and more informed

does not include existing vendors at this time.

decisions. Our team members receive support

Global Supplier Code of Conduct

through trainings, webinars, thought leadership, andFor suppliers that qualify for extended due

industry-agnostic collaboration in a range of areas.

diligence, BeiGene performs evaluations of vendor

Since 2021, we have held our suppliers to the
expectations for ethical operations outlined in our
global Supplier Code of Conduct. Each year, wereputation, which, when data is available, includes

Supplier Risk Assessments

Implement a third-party supplier risk
management program in 2023

• Third-party supplier management
program formally launched

flagging adverse media coverage pertaining tolegal events or indicators, working conditions, fairreview and update the Code to ensure that theWe expect suppliers to abide by all laws, regulations,labor practices, and environmental performance.

language and expectations remain in line withand standards regarding healthcare, as well as

This enables BeiGene to actively monitor fast-

BeiGene’s commitments. The Code covers a wide

those that address financial, labor, health, safety,changing regulatory and financial sanction lists

range of expectations from responsible business

transparency, and environmental practices. BeiGenethrough the mandatory systematic screening of

ethics to quality and management, human rights,

has an onboarding and due diligence policy thatcriminal databases, financial sanctions, and s

and workplace and environmental safety. The

informs our quality audits of manufacturing-related

elected regulatory enforcement agencies.

Code includes a significant emphasis on businesssuppliers. As part of these assessments, we evaluate

ethics, especially adherence to anti-corruption

several Responsible Business & Sustainability

With this new program, we can identify any sanction

requirements and a commitment to operate withareas, including ethics, employee health and safety,

and regulatory enforcement for new vendors quickly

honesty and integrity. As of 2023, all new masterand environmental performance. If we are awareand respond effectively if they arise. It addresses

59 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

GOAL

100%

of new vendors are screened forsanctions and regulatory enforcement
through a new third-party risk
management assessment as of 2023

Introduction

Our Approach

Local Procurement
As our suppliers play a critical role in thedevelopment and operations of our medicines,

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Direct Procurement Spend (2023)
Guangzhou & Suzhou
Sites Combined

Total Spend ($K USD)

Percentage of Total Spend in 2023

Numbers of Suppliers

Percent Total

Total spend in China

71,013

40%

71

56%

Total spend ex-China

108,608

60%

56

44%

Total spend number in 2023 basedon goods receipts

179,621

100%

127

100%

BeiGene takes care in choosing our supply chain
partners and values our supplier relationships. We
work with multiple preferred suppliers that provide
a superior level of service, high-quality products,
and consistent quality assurance on our essential
materials. To lower our environmental footprint
and ensure the continuity of supplies, BeiGene
increasingly prioritizes working with local suppliers
based in the country or region where the supplies
or services are required. This also helps support
Suppliers by Region (2023)

the communities and economies in which we arebased. In 2023, approximately $70 million of our
spending for our Guangzhou and Suzhou facilities

RegionNumber of Suppliers 2023

Percentage of Total in 2023

Countries Included Based on
2023 Purchase Orders

1,072

22.4%

U.S., Cayman Islands, Canada

0

0.0%

None

was sourced from within China.
North America

Central and South America

Europe, Middle East, and Africa

1,027

21.4%

United Arab Emirates Austria, Belgium,
Switzerland, Germany, Denmark, Spain,
Finland, France, Great Britain, Italy,
Netherlands, Norway, Poland, Sweden

Asia Pacific

596

12.4%

Australia, Japan, South Korea,
New Zealand, Singapore

China

2,100

43.8%

China

Total

4,795

100.0%*To improve the accuracy of the data used in developing our total supplier count, we utilized invoice data to determine our total supplier count. As such, the data
was assessed to align with perimeters established in the prior year. Regional counts for suppliers were based off of spend and entity location. Should a supplier
have invoiced spend in multiple regions, to avoid duplicative counting, BeiGene has allocated these suppliers to the region with the highest spend.

60 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Appendix

61 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTOur Approach

In the appendix:
GRI & HKEX Index
SASB Index
Task Force on Climate-Related
Financial Disclosures

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

GRI & HKEX Index
GRI Index

HKEX Index

Description

ResponseStatement of Use

BeiGene has reported the information cited in this GRI content index for the period January 1 – December 31, 2023, with reference to the GRI Standards.

Organizational details

BeiGene does not have a single corporate headquarters. Rather, we have administrative offices in Basel, Switzerland; Beijing, China; and Cambridge,
Massachusetts, U.S.

Entities included in the organization’s sustainability reporting

About This Report. See page 77.

Reporting period, frequency, and contact point

About This Report. See page 77.

Restatements of information

None.

GRI 2-5External assuranceThis report has not been externally assured.

GRI 2-6

Activities, value chain, and other business relationships

BeiGene is part of sector 3520: Pharmaceuticals, Biotechnology, and Life Sciences, according to the Global Industry Classification Standard (GICS). BeiGene
is a global biotechnology company that is developing and commercializing innovative medicines to improve treatment outcomes and access for patientsworldwide. BeiGene manufactures our medicines in China and is currently constructing a new manufacturing facility in the U.S.

GRI 1: Foundation 2021
GRI 1

GRI 2: General Disclosures
GRI 2-1
GRI 2-2

HKEX 15

GRI 2-3
GRI 2-4

HKEX 14: Consistency

BeiGene’s upstream value chain primarily consists of the production and transport of the materials needed to conduct R&D activities and to manufacture
and package our medicines. In addition, BeiGene relies upon a global network of clinics, hospitals, and other partners to conduct clinical trials. BeiGene’s
downstream value chain includes distribution partners and a larger network of clinics from which BeiGene’s medicines are administered to patients.
GRI 2-7

Employees

Colleague Statistics. See page 36.

GRI 2-8

Workers who are not employees

Colleague Statistics. See page 36.

GRI 2-9

Governance structure and composition

Board Structure. See page 50.
Executive Leadership Team. See page 51.
Responsible Business & Sustainability Governance. See page 51.
Additional details on our Board of Directors can be found in our 2023 Proxy Statement.
Board Structure. See page 50.

GRI 2-10

Nomination and selection of the highest governance body

GRI 2-11

Chair of the highest governance body

Board Structure. See page 50.

Role of the highest governance body in overseeing the management of
impacts

Responsible Business and Sustainability Governance. See page 51.

GRI 2-13

Delegation of responsibility for managing impacts

Responsible Business and Sustainability Governance. See page 51.

GRI 2-14

Role of the highest governance body in sustainability reporting

Responsible Business and Sustainability Governance. See page 51.

GRI 2-15

Conflicts of interest

Additional details on how we manage conflicts of interest for the Board of Directors can be found in our Corporate Governance Guidelines in the Investors
section on www.beigene.com.

GRI 2-16

Communication of critical concerns

Whistleblower and Anti-Retaliation Protection. See page 54.

Additional details on the nomination and selection of our Board of Directors can be found in our 2023 Proxy Statement.

GRI 2-12

HKEX 13 (i, ii, iii)

Reporting Misconduct Policy

62 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

GRI Index

HKEX Index

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Description

Response

GRI 2-17

Collective knowledge of the highest governance body

Board Structure. See page 50.

GRI 2-18

Evaluation of the performance of the highest governance body

The directors are evaluated and appointed/removed by shareholders. The Nominating and Corporate Governance Committee is responsible for establishingprocedures for identifying and evaluating board of director candidates, including nominees recommended by shareholders, and overseeing the evaluationof the Board of Directors and management. Further details on our Board of Directors and their nomination structure can be found in our Nominating &Corporate Governance Charter and 2023 Proxy Statement.

GRI 2-19

Remuneration policies

In 2024, BeiGene restructured its executive compensation structure to include the use of performance share units (PSUs). All executives with the title SeniorVice President and above will have the following compensation mix:
• 1/3 PSUs
• 1/3 Restricted Share Units (RSUs)• 1/3 Options

In addition, a Compensation Recovery Policy, otherwise known as a clawback policy, has been implemented.
Details on remuneration can be found in our 2023 Proxy Statement.
GRI 2-20

Process to determine remuneration

The Compensation Committee of the Board of Directors is responsible for determining remuneration for our executive officers. Details on our remuneration
policies and approach for our executive officers can be found in our 2023 Proxy Statement and Compensation Committee Charter.

GRI 2-21

Annual total compensation ratio

Compensation and Benefits. See page 31.

GRI 2-22

Statement on sustainable development strategy

A Letter from Leadership. See page 3.
Our Material Topics. See page 7.
Our Climate Strategy. See page 42.

GRI 2-23

Policy commitments

Guiding Principles. See page 6.
United Nations Global Compact & Sustainable Development Goals. See page 9.

GRI 2-24

Embedding policy commitments

Business Ethics. See page 54.

GRI 2-25

Processes to remediate negative impacts

BeiGene is required to carefully monitor the safety of its products from first use in humans through post-commercialization. The company acts upon any
potential safety issues identified by patients or others through ethics committees or Institutional Review Boards.
Patient Safety. See page 19.
Product Quality Control Systems. See page 56.
Our Climate Strategy. See page 42.

GRI 2-26

HKEX KPI B7.2

Mechanisms for seeking advice and raising concerns

Whistleblower and Anti-Retaliation Protection. See page 54.

GRI 2-27

Compliance with laws and regulations

In 2023, BeiGene did not have any material instances of non-compliance in which fines or non-monetary sanctions were incurred.

GRI 2-28

Membership associations

BeiGene is a member of the UN Global Compact, the U.S. National Medical Association, the Bloomberg International Cancer Coalition, and Procurement
Leaders, among others.

GRI 2-29

Approach to stakeholder engagement

Stakeholder Engagement. See page 52.

GRI 2-30

Collective bargaining agreements

BeiGene has not entered into any collective bargaining agreements in the U.S., APAC, Europe, or Latin America, except that BeiGene is enrolled in the
SINACAMESP commercial trade union in Brazil because of a local law obligation.

63 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

GRI Index

HKEX Index

Our Approach

AdvancingGlobal Health

Description

Response

Process to determine material topics

Our Material Topics. See page 7.

List of materials topics

Our Material Topics. See page 7.

Disclose the process to identify material ESG factors and if stakeholder
engagement is conducted

Our Material Topics. See page 7.
Stakeholder Engagement. See page 52.

Management approach

A Differentiated Approach. See page 14.
Our Approach to Advancing Global Health Equity. See Page 15.

Empowering
Our Colleagues

GRI 3: Material Topics 2021
GRI 3-1
GRI 3-2
HKEX 14: Materiality and
Quantitative

BeiGene Material Topic: Innovative Products
GRI 3-3
Non-GRI Topic

A Differentiated Approach. See page 14.

BeiGene Material Topic: Charitable Giving & Volunteerism
GRI 3-3Management approach

Non-GRI Topic

Employee Volunteerism. See Page 37.
Employee Volunteerism See Page 37.

BeiGene Material Topic: Access and Affordability
GRI 3-3Management approach

Non-GRI Topic

Pursuing Broad Access to Our Medicines. See Page 20.
SASB Disclosures HC-BP-240a and HC-BP-240b. See Page 74.

GRI 204: Procurement Practices 2016 (BeiGene Material Topic: Responsible Sourcing)
GRI 3-3

HKEX Aspect B5 and KPI B5.2

Management approach

Responsible Procurement. See page 59.
Supplier Risk Assessments. See page 59.

Policies on managing environmental and social risks of the supply chain
GRI 204-1

Proportion of spending on local suppliers

Local Procurement. See page 60.

HKEX KPI B5.1

Number of suppliers

Local Procurement. See page 60.

HKEX KPI B5.3

Practices used to identify environmental and social risks

Supplier Risk Assessments. See page 59.

GRI 206: Anti-Competitive Behavior 2016 (BeiGene Material Topic: Business Ethics and Integrity)
GRI 3-3Management approach

Business Ethics. See page 54.

GRI 206-1

Legal actions for anti-competitive behavior, anti-trust, and monopoly
practices

Reference page 114 of our 2023 Form 10-K for information on our legal matters.

64 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

GRI Index

HKEX Index

Description

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Response

GRI 301: Materials 2016 (BeiGene Material Topic: Product Stewardship)
GRI 3-3

HKEX A1, A2, A3, and A4

Management approach

BeiGene is committed to acting as a responsible environmental steward. This includes minimizing our use of materials, energy, and water and reducing theamount of waste produced by our operations.
BeiGene only has active manufacturing facilities in China. We comply with relevant laws and regulations, including the Environmental Protection Law of thePeople’s Republic of China, Water Pollution Prevention Law of the People’s Republic of China, Law of the People’s Republic of China on the Prevention andControl of Environmental Pollution by Solid Waste, and Regulations on the Administration of Construction Project Environmental Protection.
We also maintain a robust EHS program to ensure sound environmental practices in our laboratory, clinical trial, manufacturing, and office settings. Our EHS
management system is based on the ISO14001 framework, and two of our facilities in Guangzhou and Suzhou are certified ISO14001 compliant. Our system
includes our EHS Management System Manual, which has corresponding policies and SOPs.
For example, we maintain management procedures for wastewater, gas emissions, leak prevention, and solid waste, among others. We regularly review andupdate our SOPs. To assess risk, we conduct regular internal assessments. External assessments are periodically conducted at our manufacturing and R&D
sites by governmental agencies, including the Environmental Protection Bureau and Police Bureau.
Our Global Head of Technical Operations and Manufacturing is responsible for overseeing and directing overall EHS management and is supported by theEHS department that integrates EHS considerations into our business.
2023 Goals & Progress. See page 40.

GRI 301-1

HKEX A2.5

Materials used by weight or volume

BeiGene does not yet collect information outside of packaging materials used for finished products.
Packaging Use (tonnes)

2021

2022

2023

Total packaging material used for finished medicines

94

132

200

Packaging material used per kg of internally manufactured commercial product (tonnes/kg
commercial product)

0.006

0.005

0.004

GRI 301-2

Recycled input materials used

BeiGene does not yet collect this information.

GRI 301-3

Reclaimed products and their packaging materials

BeiGene does not yet collect this information.

GRI 302: Energy 2016 (BeiGene Material Topic: Climate Change)
GRI 3-3

HKEX A2.3

Management approach

See Materials: Management Approach (GRI 301-3-3).
Our Climate Strategy. See page 42.
Our Climate Risk Management. See page 45.

GRI 302-1

HKEX A2.1

Energy consumption within the organization

Our Climate Metrics. See page 46.

65 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTEnergy Use (MWh)

2021

2022

2023

Total energy consumption

82,977

122,385

160,189

Direct energy consumption

10,585

14,761

5,936

Natural gas
Mobile9,066
803

11,455
3,230

4,041
1,454

Diesel fuel

717

76

441

Indirect energy consumption

72,392

107,625

154,252

Electricity
Steam

47,78024,612

68,97038,65598,36455,888

Total energy consumption per kg of internally manufactured commercial product (MWh/kg
commercial product)

4.99

4.7

3.17

Introduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

GRI Index

HKEX Index

Description

Response

GRI 302-2

HKEX A2.1

Energy consumption outside of the organization

BeiGene does not currently track this information, but please reference our Scope 3 Inventory on page 46.

GRI 302-3

HKEX A2.1

Energy intensity

Our Climate Strategy. See page 42.
Our Climate Metrics. See page 46.
See GRI 302-1.

GRI 302-4

Reduction of energy consumption

Our Climate Metrics. See page 46.
See GRI 302-1.

GRI 302-5

Reductions in energy requirements of products and services

Not applicable.

OperatingResponsibly

Appendix

GRI 303: Water and Effluents 2018 (BeiGene Material Topic: Product Stewardship)
GRI 3-3Management approach

See Materials: Management Approach (GRI 301-3-3).
Our Climate Governance. See page 41.

Interactions with water as a shared resource

BeiGene operates two main manufacturing facilities located in Guangzhou and Suzhou, China. The locations of our Guangzhou and Suzhou facilities are
rated as Medium-High and High, respectively, for overall water risk according to WRI Aqueduct as assessed on January 25, 2022. We have not experienced
any issues sourcing water for our operations. We continue to explore opportunities for reducing our water use in these locations. See Our Climate Metrics,
pages 46.

GRI 303-2

Management of water discharge-related impacts

Our R&D centers and manufacturing plants are equipped with wastewater treatment facilities, and we conduct monitoring to ensure that the treated water
meets national and local standards. The industrial wastewater from the Suzhou plant is 100 percent recycled after being treated. The sanitary sewage fromour plants is discharged into the municipal pipelines in accordance with the local standards. We engage qualified testing institutions to conduct regularwastewater discharge testing. In 2023, we did not find any cases in which wastewater exceeded the local standards.

GRI 303-3

Water withdrawal

GRI 303-1

HKEX A2.4

GRI 303-4
GRI 303-5

HKEX A2.2

Water Use (cubic meters)

2021

2022

2023

Total water consumption

359,004

735,420

719,875

Production water consumption

342,172

673,844

659,463

Other water consumption

16,832

61,57760411

Recycled water

2,388

5,010

6,709

Wastewater

66,156

158,496

182,394

Chemical oxygen demand

5.24

7.86

16

Ammonia nitrogen

0.44

0.98

1

Water consumption per kg of internally manufactured commercial product (cubic meters/kg
commercial product)

21.6

28.27

14.25

Wastewater consumption per kg of internally manufactured commercial product (cubic meters/
kg commercial product)

3.98

6.09

3.61

Water discharge

See GRI 303-3.

Water consumption

See GRI 303-3.

GRI 305: Emissions 2016 (BeiGene Material Topic: Climate Change)
GRI 3-3

HKEX A1.5

Management approach

66 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

See Materials: Management Approach (GRI 301-3-3).
Our Climate Strategy. See page 42.
Our Climate Risk Management. See page 45.

Introduction

GRI Index

HKEX Index

Description

GRI 305-1

HKEX A1.1-A1.2

Direct (Scope 1) GHG emissions

GRI 305-2

HKEX A1.1-A1.2

GRI 305-3

Indirect (Scope 2) GHG emissions

Other indirect (Scope 3) GHG emissions

AdvancingGlobal Health

Our Approach

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Response
GHG Emissions (tonnes CO2e)

2021

2022

2023

Direct GHG emissions (Scope 1)

2,442

3,391

2,463

Natural gas

1,815

2,316

826

Mobile

210

850

1,454

Diesel fuel

192

22

112

Refrigerant loss

187

143

0

CO2 purchased

38

60

71

GHG Emissions (tonnes
CO2e) - Market Based

2021

2022

2023

GHG Emissions (tonnes
CO2e) - Location Based

2021

2022

2023

Indirect GHG emissions(Scope 2)35,90053,86776,465

Indirect GHG emissions(Scope 2)35,89853,87076,485

Electricity

26,15438,56054,351

Electricity

26,152

38,56354,371

Steam

9,746

15,307

22,114

Steam

9,746

15,307

22,114

GHG Emissions tonnes CO2e)

2021

2022

2023

Other indirect GHG emissions (Scope 3)

285,755

217,158

476,965

1.

Purchased goods and services

228,616

140,499

333,8442.

Capital goods

28,88139,401

97,211

3.

Fuel- and energy-related activities not included in scopes 1 or 2

13,711

14,25021,678

4.

Upstream transportation and distribution

3,577

1,397

1,694

5.

Waste generated in operations

31

276

139

6.

Business travel

2,423

11,6216,380

7.

Employee commuting

8,514

6,100

7,193

8.

Upstream Leased Assets

N/A

3,537

8,701

12.

End-of-life treatment of sold products

1

77

127

Note: Category 9 Downstream Transportation and Distribution has been deemed de minimis, and Categories 10, 11, 13, 14, and 15 have been deemed not relevant to BeiGene.
For Category 8 Upstream Leased Assets: In 2021 WPS facilitates were accounted for under Scope 1 & 2. Beginning in 2022, these facilities have been accounts for under
Scope 3 as they are leased and BeiGene does not have direct operational control.

GRI 305-4

HKEX A1.1-A1.2

GHG emissions intensity

67 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTAppendix

Our Climate Metrics. See page 46.

GHG Emissions (tonnes CO2e)

2,021

2022

2023

Total GHG emissions per kg of internally-manufactured commercial product (tonnes CO2e/kg
commercial product) [Scopes 1 and 2]

2.31

2.2

1.56

Introduction

GRI Index

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Description

Response

GRI 305-5

Reduction of GHG emissions

Our Climate Metrics. See page 46.

GRI 305-6

Emissions of ozone-depleting substances (ODS)

Not applicable.

Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air
emissions

Apart from GHG emissions, our major air emissions include SO2 and NOx generated from natural gas consumption during production, and a small volume ofwaste gas generated during laboratory operations. SO2 and NOx emissions are discharged after being processed by waste gas treatment facilities to ensurethat SO2 and NOx concentrations meet the emission standards set by the local authority. Waste gas from the laboratories is discharged through fume hoods,
and a treatment device has been installed at the end of the ventilation system in each laboratory to ensure we meet emissions standards.

GRI 305-7

HKEX Index

Our Approach

HKEX A1.1-A1.2

We engage qualified testing institutions to conduct regular air emissions discharge testing. In 2023, we did not find any cases in which emissions exceeded
the local standards.

Air Emissions (tonnes)

2021

2022

2023

SO2 emissions
NOx emissions
VOC emissions

0.13
0.2
2.63

0.07
0.4
2.33

0.01
0.6
2.88

GRI 306: Supplier Environmental Assessment 2016 (BeiGene Material Topic: Responsible Sourcing)			
GRI 3-3
GRI 306-1

HKEX A1.6

GRI 306-2
GRI 306-3

HKEX A1.3 and A1.4

Management approach

See Materials: Management Approach (GRI 301-3-3).
Our Climate Governance. See page 41.

Waste generation and significant waste-related impacts

Our non-hazardous waste includes domestic waste produced in office operations and non-hazardous waste from production. Non-hazardous waste
produced in manufacturing and R&D facilities is disposed of by municipal sanitary stations. Domestic waste produced in office operations is handled byproperty management companies, with whom we collaborate to recycle items such as cardboard boxes, glass, plastic, and paper. Our operation sites follow
waste sorting standards and abide by local laws and regulations. Hazardous waste produced in manufacturing and laboratories is collected and stored incompliance with applicable laws and regulations and transported to qualified third-party vendors for disposal.

Management of significant waste-related impacts

See above.

Waste generated

Our Climate Metrics. See page 46.

Waste (tonnes)

2021

2022

2023

Hazardous waste
Non-hazardous waste

414
281

532
515

678
715

Hazardous waste per kg of internally manufactured commercial product(tonnes/kg commercial product)

0.02

0.02

0.01

Non-hazardous waste per kg of internally manufactured commercial product(tonnes/kg commercial product)

0.02

0.02

0.01

GRI 306-4

Waste diverted from disposal

BeiGene does not yet collect this information.

GRI 306-5

Waste directed to disposal

BeiGene does not yet collect this information.

GRI 308: Supplier Environmental Assessment 2016 (BeiGene Material Topic: Responsible Sourcing)
GRI 3-3
GRI 308 -1

HKEX KPI B5.4

Management appraoch

Scope 3 Reduction Strategy. See page 44.
Supplier Risk Assessments. See page 59.

Engagement with suppliers to improve environmental performance

Scope 3 Reduction Strategy. See page 44.
Supplier Risk Assessments. See page 59.

68 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

GRI Index

HKEX Index

Description

AdvancingGlobal Health

Our Approach

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Response

GRI 401: Employment 2016 (BeiGene Material Topic: Colleague Engagement & Well-Being)
GRI 3-3

GRI: 401-1

HKEX KPI B1.1-B1.2

Management approach

Colleague Engagement & Support. See page 29.
Global Supplier Code of Conduct. See page 59.

Total number and rate of new employee hires and turnover during thereporting period, by age group, gender, and region

See tables below:
New Employee Hires

Employee Turnover

Employee Hires

2021

2022

2023

Turnover (%)

2021

2022

2023

Total

5,026

3,431

3,281

Total

21%

18%

14%

BeiGene Employees

4,271

2,705

2,625

Female

19%

17%

12%

Contingent Workers

755

726

566

Male

25%

21%

15%

16%

By Employment TypeBy Gender (%)

By Gender (%)

By Age (%)

Female

55%

58%

55%

30 & under

23%

21%

Male

45%

42%

45%

31-50

20%

17%

13%

51-65

16%

15%

11%

65 & above

23%

26%

35%

By Age (%)
30 & under

55%

45%

46%

31-50

41%

48%

48%

By Region (%)

51-65

3%

7%

6%

APAC

23%

19%

15%

65 & above

<1%

<1%

<1%

North America

17%

19%

12%

By Region (%)

GRI 401-2

Benefits provided to full-time employees that are not provided totemporary or part-time employees

APAC

84%

75%

72%

North America

13%

16%

16%

EMEA

3%

9%

10%

Latin America

0%

0%

2%

EMEA

18%

7%

5%

Latin America

0%

0%

0%

In the U.S., we offer medical, dental, vision, life insurance, and disability insurance; fertility/adoption services; family support services; wellness programs; anda 401(k) retirement plan that has been increased to reflect 6% percent matching. Our health insurance programs also provide coverage for travel and lodging
should our employees need to travel to receive the care they need. We also contribute 50 percent of the deductible toward a Health Savings Account with
our high-deductible medical plan option. In other parts of the Americas and EMEA, we offer statutory coverages and supplemental coverages, which may
include a pension; medical, dental, vision, life and disability insurance; and wellness programs.
In China, we provide social insurance, commercial insurance, wellbeing programs which include the Employee Assistance program and festival gifts to all
full-time employees. For social insurance, BeiGene contributes to the employee’s social security account. Additionally, our comprehensive commercial
plan covers medical in-patient benefits with a 100 percent reimbursement, medical out-patient benefits with a 90 percent reimbursement, critical illness
insurance, life insurance, accidental insurance, and global travel insurance, among others.
In Australia, New Zealand, Singapore, South Korea, Japan, Thailand, and Malaysia we offer both statutory benefit plans and supplemental benefit plans
recognized by local practice, including individual medical insurance reimbursement, home office assistance, flu vaccine support, global travel insurance, andstatutory pension plans (where applicable), as well as a defined contribution plan for South Korea. In Australia and New Zealand, we also provide commercial
life and income protection insurance to employees.
Additional programs can also be found in Compensation and Benefits. See page 31.

69 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

GRI Index

HKEX Index

GRI 401-3

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

Description

Response

Parental leave benefits

In the U.S., Canada, and EMEA, BeiGene offers full pay for a minimum of 12 weeks of parental leave in combination with statutory programs for all parents. In
some countries, such as Canada, the combination of statutory and BeiGene parental leave may provide longer periods of full pay such as 18 weeks for thebirthing mother.
In China, we follow local regulations, which vary by province. The minimum national requirements include 128 days full paid maternity leave and seven days
full paid paternity leave; however, different cities/provinces will have different requirements.
In Australia and New Zealand, for all eligible employees who complete 12 months’ service in BeiGene, we offer 12 weeks full paid maternity leave on top of
the state standard as well as two weeks full paid paternity leave on top of state standard. In the rest of the Asia Pacific (APAC), we follow country-specificparental leave guidelines.
Below is a summary chart of parental leave taken by region in 2023:

HKEX Aspect B1: Employment

Information on the policies and compliance with relevant laws andregulations that have a significant impact on the issuer, relating tocompensation and dismissal, recruitment and promotion, working hours,
rest periods, equal opportunity, diversity, anti-discrimination, and otherbenefits and welfare

Parental Leave

APAC

Americas

EMEA

Men entitled to parental leave

3417

679

237
5

Men that took parental leave

59

26

Total male employees that returned to work in the reporting period after parental leave ended

59

26

5

Females entitled to parental leave

4738

948

381

Females that took parental leave

264

52

13

Total female employees that returned to work in the reporting period after parental leave ended

262

52

13

We maintain compliance with relevant laws and regulations related to employment, including, but not limited to, the U.S. Civil Rights Act of 1964; U.S.
Americans with Disabilities Act; U.S. Age Discrimination in Employment Act; U.S. Equal Pay Act; U.S. Employee Retirement Income Security Act; Labor Law of
the People’s Republic of China; Labor Contract Law of the People’s Republic of China; Law of the People’s Republic of China on the Protection of Women’s
Rights and Interests; Social Insurance Law of the People’s Republic of China; Provision on Minimum Wage of the People’s Republic of China; Swiss Code ofObligations; German Civil Code; French Labour Law; Italian Civil Code; UK Employment Rights Act 1996; and Spanish Civil Code and its Collective Bargaining
Agreements.

GRI 403: Occupational Health and Safety 2018 (BeiGene Material Topic: Colleague Engagement & Support)
GRI 3-3Management approach

We maintain a robust EHS program to ensure the safety of our workforce in laboratory, clinical trial, manufacturing, and office settings. We are committed tocreating a safety culture—one that fosters a safe work environment to promote employee health and well-being. Our EHS management system is based on
ISO 14001 and 45001 frameworks. The system includes our EHS Management System Manual, which includes corresponding policies and SOPs, such as our
Restricted Space Management Procedure, Procedure for Explosive Chemicals Management, and Occupational Health Management Procedure, to manage
and control occupational health and safety risks. We regularly review and update our SOPs.
Our Global Head of Technical Operations and Manufacturing is responsible for overseeing and directing overall EHS management and is supported by theEHS department that integrates EHS considerations into our business. In 2023, a total of 227 employees in manufacturing and R&D facilities, or 56.39 percent
of front-line employees, were represented by a formal EHS committee.

70 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

AdvancingGlobal Health

Our Approach

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

GRI Index

HKEX Index

Description

Response

GRI 403-1, 403-2
and 403-3

HKEX KPI B2.3

Hazard identification, risk assessment, and incident investigation

We conduct regular safety inspections and internal EHS audits. We have also established an emergency response system to deal with natural disasters,
medical emergencies, fire and explosion emergencies, and chemical spills, among others. We carry out relevant emergency drills regularly to ensure that
employees are trained on emergency procedures. All first aid specialists in the plants have received professional training delivered by the local Red Cross,and in our manufacturing facility in Guangzhou, China, we employ a full-time nurse on staff.

Occupational health and safety management system
Description of occupational health and safety measures adopted, andhow they are implemented and monitored, and communication on
occupational health and safety

External assessments are periodically conducted at our manufacturing and R&D sites by governmental agencies, including the Environmental Protection
Bureau and Police Bureau. When designing new facilities, we employ qualified third parties to evaluate and design safety features to mitigate risks within ourfacilities and production lines. Each manufacturing facility and R&D site has an EHS committee comprising of leadership and frontline employees to promotea safety culture, review performance scorecards, investigate safety near misses or incidences, and implement corrective actions.
Health & Safety. See page 38.
See GRI 403-3-3 for our approach to EHS management.

GRI 403-4

Worker participation, consultation, and communication on occupational
health and safety

Each manufacturing facility and R&D site has an EHS committee comprising leadership and frontline employees to promote a safety culture, review
performance scorecards, investigate safety near misses or incidences, and implement corrective actions.

GRI 403-5

Worker training on occupational health and safety

We conduct occupational health and safety trainings for all our employees and third parties on a regular basis to enhance occupational health and safety
awareness and improve their capabilities to cope with safety incidences. Our employees who engage in higher-risk work activities are required to takeadditional trainings or receive certifications before performing certain tasks. Employees are provided with appropriate personal protective equipment to
reduce potential exposure.

GRI 403-7

Prevention and mitigation of occupational health and safety impacts
directly linked by business relationships

Responsible Procurement. See page 59.
Supplier Risk Assessments. See page 59.

GRI 403-8

Workers covered by an occupational health and safety management
systemAll of the employees and contractors in our manufacturing and R&D facilities are covered by our EHS management system.

Work-related injuries and ill health fatalities

Health & Safety. See page 38.

GRI 403-9 and403-10HKEX KPI B2.1 and B2.2

Total injury rate
Lost days due to work injury

HKEX Aspect B2: Health and
SafetyInformation on the policies and compliance with relevant laws andregulations that have a significant impact on the issuer relating toproviding a safe working environment and protecting employees fromoccupational hazards

Health and Safety
Performance in
Manufacturing Facilities*

2021

2022

2023
0.05

Total Incident Rate

0

0.13

Lost Time Incident Rate

0

0.07

0

Fatalities

0

0

0

We strictly comply with the applicable laws related to occupational health and safety, such as the workplace safety standards set by the federal U.S.
Occupational Safety and Health Administration or state/local safety standards, the Law of the People’s Republic of China on Prevention and Control ofOccupational Diseases, the Technical Specification for Occupational Health Surveillance, the Law of the People’s Republic of China on the Prevention andTreatment of Infectious Diseases, and the Provisions of the State Council on the Investigation of Administrative Responsibility for Major Safety Accidents.
See GRI 403-3-3 for our approach to EHS management.

GRI 404: Training and Education 2016 (BeiGene Material Topic: Colleague Engagement & Support)
GRI 3-3

HKEX Aspect B3Management approach

Career Development. See page 33.

GRI 404-1

HKEX KPI B3.2

The average training hours completed by gender and employee
category

BeiGene does not track training hours per employee at this time. For more information, see Education & Training Opportunities, page 33.

Programs for upgrading employee skills and transition assistanceprogram

Career Development. See page 33.

GRI 404-2

BeiGene provides assistance programs to facilitate continued employability for those employees separated from the company.

71 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

GRI Index

HKEX Index

GRI 404-3
HKEX KPI B3.1

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

Description

Response

Percentage of employees receiving regular performance and careerdevelopment reviews

One hundred percent of BeiGene’s employees receive regular performance and career development reviews.

The percentage of employees trained by gender and employee
category

BeiGene was not able to collect this data in 2023 but is working to add this reporting capability in the future.

OperatingResponsibly

Appendix

GRI 405: Diversity and Equal Opportunity 2016 (BeiGene Material Topic: Diversity, Equity, Inclusion & Belonging)
GRI 3-3Management approach

A Culture of Belonging. See page 35.

GRI 405-1

Diversity of governance bodies and employees

Colleague Statistics. See page 36.
Board Structure. See page 50.
Executive Leadership Team. See page 51.

GRI 405-2

Ratio of basic salary and remuneration of women to men

Compensation & Benefits. See page 31.

GRI 406: Non-discrimination 2016 (BeiGene Material Topic: Diversity, Equity, Inclusion & Belonging)
GRI 406-1

Incidents of discrimination and corrective actions taken

We are not aware of any incidents of material non-compliance with applicable laws and regulations relating to incidents of discrimination in 2023.

GRI 414: Supplier Social Assesment 2016 (BeiGene Material Topic: Responsible Sourcing)
GRI 414Engagement with suppliers to improve social performance

Stakeholder Engagement. See page 52.
Supplier Risk Assessments. See page 59.

GRI 416: Customer Health and Safety 2016 (BeiGene Material Topic: Patient Engagement & Advocacy)
GRI 416-2

HKEX KPI B6.1

Incidents of non-compliance concerning the health and safety impacts
of product and services;

0 recalls issued in 2023.

Percentage of total products sold or shipped subject to recalls for safety
and health reasons
HKEX Aspect B6Information on the policies and compliance with relevant laws andregulations that have a significant impact on the issuer relating tohealth and safety, advertising, labeling, and privacy matters relating to
products and services provided, and methods of redress

Patient Safety. See pages 19.
Product Quality Control Systems. See page 56.
Responsible Marketing. See page 58.
In addition, we strive to maintain compliance with the evolving regulatory environment related to product responsibility including, but not limited to,compliance with the ICH Q10 Drug Quality Control System; U.S. Federal Food, Drug, and Cosmetic Act; California Consumer Privacy Act; regulations fromthe U.S. Food and Drug Administration; EU General Data Protection Regulations (“GDPR”); Patent Law of the People’s Republic of China; Regulation on the
Administration of Human Genetic Resources of the People’s Republic of China; and China Personal Information Protection Law.

HKEX KPI B6.2

Number of products and service-related complaints received and how
they are dealt with

72 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Quality Assurance. See page 56.

Introduction

GRI Index

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

HKEX Index

Description

Response

HKEX KPI B6.3

Description of practices relating to observing and protecting intellectual
property rights

Our commercial success depends on our ability to develop and protect our inventions, proprietary technology, and knowledge. We strictly abide by andkeep abreast of the requirements of relevant laws and regulations related to intellectual property rights in the countries and regions in which we operate. We
also provide training to employees to raise their awareness of intellectual property protection and BeiGene’s policies and procedures at least every quarter.
We have filed and continue to pursue patent applications and obtained patents in the U.S., Europe, China, and other countries, relating to our medicines,
drug candidates, and technologies. In addition, we have updated our employee inventor remuneration policy to further encourage drug innovation and new
drug development, and we comply with all applicable laws and regulations regarding inventor remuneration. Our position is laid out in Our Global Statement
on Patents and Intellectual Property.
We avoid infringing on the valid patents and other intellectual property rights of third parties by conducting Freedom to Operate (FTO) analyses to makesure that the development and commercialization of our medicines do not infringe others’ valid patent rights. In certain cases, we rely on in-licensing
opportunities to develop, strengthen, and support our development programs. We conduct intellectual property due diligence for in-license and out-license
projects to minimize intellectual property risks.
Protecting Against Counterfeit & Illicit Medicines . See page 56.
Responsible Marketing. See page 58.

HKEX KPI B6.4

Description of quality assurance process and recall procedures

Quality Assurance. See page 56.

GRI 417: Marketing and Labeling 2016 (BeiGene Material Topic Business Ethics and Integrity)
GRI 3-3Management approach

Responsible Marketing. See page 58.

GRI 417-1

Requirements for product and service information and labelingResponsible Marketing. See page 58.

GRI 417-2

Incidents of non-compliance concerning product and service
information and labeling

In 2023, we are not aware of incidents of non-compliance concerning product and service information and labeling.

GRI 417-3

Incidents of non-compliance concerning marketing communications

In June 2023, Pharmacyclics filed a patent infringement suit against BeiGene in the U.S. District Court for the District of Delaware, alleging that BeiGene’scommercialization of BRUKINSA infringes it U.S. Patent No. 11,672,803 (“the 803 Patent”). While BeiGene respects valid intellectual property rights, BeiGenestrongly believes that the 803 Patent is overly broad and invalid. BeiGene will vigorously defend against Pharmacyclics’ claims. Our formal press release canbe found here.

GRI 418: Customer Privacy 2016 (BeiGene Material Topic: Patient Engagement & Advocacy)
GRI 3-3
GRI 418-1

HKEX B6.5

Management approach/description of consumer data protection andprivacy policies and how they are implemented and monitored

Data Privacy & Cybersecurity. See page 55.

Substantiated complaints concerning breaches of customer privacy andlosses of customer data

BeiGene did not receive any complaints concerning breaches of customer privacy or losses of customer data. Nor we have experienced any breach in 2023.

73 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

Appendix

SASB Index
SASB Index

Description

Response

210a.1

Discussion, by world region, of management process for ensuring quality and patient safety during
clinical trials

BeiGene is part of sector 3520: Pharmaceuticals, Biotechnology, and Life Sciences, according to the Global Industry Classification Standard (GICS). BeiGene
is a global biotechnology company that is developing and commercializing innovative medicines to improve treatment outcomes and access for patientsworldwide. BeiGene manufactures our medicines in China and, in 2022, broke ground on a new manufacturing facility in the U.S.
BeiGene’s upstream value chain primarily consists of the production and transport of the materials needed to conduct R&D activities and to manufacture
and package our medicines. In addition, BeiGene relies upon a global network of clinics, hospitals, and other partners to conduct clinical trials. BeiGene’s
downstream value chain includes distribution partners and a larger network of clinics from which BeiGene’s medicines are administered to patients.
Quality Assurance. See page 56.
Clinical Trial Excellence. See page 16.
Patient Safety. See page 19.
Data Privacy & Cybersecurity. See page 55.

210a.2

Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilancethat resulted in: Voluntary Action Indicated (VAI) and Official Action Indicated (OAI)

We currently do not report on this information.

210a.3

Total amount of monetary losses as a result of legal proceedings associated with clinical trials
in developing countries

Reference page 114 of our 2023 Form 10-K for information on our legal matters.

240a.1

Description of actions and initiatives to promote access to health care products for priority diseases
and in priority countries as defined by the Access to Medicine Index

Expanded Access Programs. See pages 21.
Improving Access for Chronic Lymphocytic Leukemia (CLL) Patients (Max Foundation). See page 21.

240a.2

List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of
Medicines Programme (PQP)

There is currently no BeiGene product on the list.

240b.1

Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved
payments and/or provisions to delay bringing an authorized generic product to market for a definedtime period

Reference page 114 of our 2023 Form 10-K for information on our legal matters.

240b.2

Percentage change in: average list price and average net price across U.S. product portfolio
compared to previous year

We currently do not report on this information.

240b.3

Percentage change in: list price and net price of product with largest increase compared to previous
year

We currently do not report on this information.

250a.1

List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts
for Human Medical Products database

FDA Adverse Event Reporting System (FAERS) Public Dashboard

250a.2

Number of fatalities associated with products as reported in the FDA Adverse Event Reporting
System

FDA Adverse Event Reporting System (FAERS) Public Dashboard

250a.3

Number of recalls issued, and total units recalled

0 recalls issued in 2023.

250a.4

Total amount of product accepted for takeback, reuse, or disposal

In 2023, BeiGene developed a partnership with the Pharmaceutical Product Stewardship Work Group (PPSWG) in the U.S. It is their mission to provide
infrastructure, guidance, and subject matter expertise to support member compliance and improve awareness of existing pharmaceutical takeback programs
and options for consumers. We do not currently track the amount of product returns on a global basis.

250a.5

Number of FDA enforcement actions taken in response to violations of current Good Manufacturing
Practices (cGMP), by type

We currently do not report on this information.

74 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

SASB Index

Description

Response

260a.1

Description of methods and technologies used to maintain traceability of products throughout
the supply chain and prevent counterfeiting

Protecting Against Counterfeit & Illicit Medicines. See page 56.

260a.2

Discussion of process for alerting customers and business partners of potential or known risks
associated with counterfeit productsProtecting Against Counterfeit & Illicit Medicines. See page 56.

260a.3

Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related
to counterfeit productsProtecting Against Counterfeit & Illicit Medicines. See page 56.

270a.1

Total amount of monetary losses as a result of legal proceedings associated with false marketingclaimsReference page 114 of our 2023 Form 10-K for information on our legal matters.

270a.2

Description of code of ethics governing promotion of off-label use of products

Responsible Marketing. See page 58.

330a.1

Discussion of talent recruitment and retention efforts for scientists and research and development
personnel

Building Our Team. See page 28.

Innovating
Sustainably

OperatingResponsibly

Appendix

Career Development. See pages 33.
See GRI Chart 401-1.
330a.2

Voluntary and involuntary turnover rate for: executives/senior managers, mid-level managers,
professionals, and all others

Colleague Engagement & Support. See page 29.

430a.1

Percentage of entity’s facilities and Tier I suppliers’ facilities participating in the Rx-360 International
Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for
integrity of supply chain and ingredients.

Supplier Risk Assessments. See pages 59.

510a.1

Total amount of monetary losses as a result of legal proceedings associated with corruption andbribery

Reference page 114 of our 2023 Form 10-K for information on our legal matters.

510a.2

Description of code of ethics governing interactions with health care professionals

Business Ethics. See page 54.
Anti-Bribery & Corruption. See page 54.
Responsible Marketing. See page 58.
We implement anti-corruption control measures and strictly follow relevant laws and regulations against corruption, extortion, fraud, bribery, and unfair
competition, such as the Sarbanes-Oxley (SOX) Act, the U.S. Anti-Kickback Statute, UK Antibribery Act, the U.S. Foreign Corrupt Practices Act, and the Law of
the People’s Republic of China against Unfair Competition.

000.A

Number of patients treated

Expanding Our Commercial Presence. See page 20.

000.B

Number of drugs in portfolio, and in research and development (Phases 1-3)

See Pipeline and Our Medicines on the BeiGene corporate website, www.beigene.com.

75 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTIntroduction

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Task Force on Climate-Related Financial Disclosures
In this index, we provide guidance to where we disclose information regarding our strategy, risks, governance and metrics related to climate change and its
potential impacts, positive or negative, on our business and our stakeholders. We reference the structure outlined by the Task Force on Climate Related Financial
Disclosures and provide information to the extent that it is available and suitable for public dissemination. We also include information regarding short-, medium-,and long-term risks and opportunities presented by climate change, our research on the potential impacts of climate change to our business, and our efforts toengage stakeholders in these discussions.
Over the past two years, we have also explored different climate scenarios to better understand the risks and opportunities across our operations and how they may
impact our company now and in the future. Our goal is to make our business more resilient and to recognize and leverage emerging opportunities for growth.

Strategy

For information regarding our strategy to address climate change, please see pages 42-44 in this report.

Governance

For information regarding governance issues related to climate change, please see page 41 in this report.

Risks

For information regarding how we assess and analyze risks related to climate change, please see page 45 in this report.

Metrics

For information regarding metrics related to our performance relevant to climate change, please see pages 46-47 in this report.

76 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

About This Report
BeiGene reports on our Responsible Business & Sustainability
performance annually. This report covers BeiGene’s performance inthe fiscal year 2023, which ended on December 31, 2023, and aligns
with our financial reporting. The report, published on April 26, 2024,
was developed in reference to the Global Reporting Initiative (GRI)
Standards, the Sustainability Accounting Standards Board (SASB),
and the Task Force on Climate-Related Financial Disclosures (TCFD).
This report was developed using principles of accuracy, balance,clarity, comparability, completeness, sustainability context, andtimeliness and also serves as BeiGene’s RB&S Report in accordancewith Appendix 27: Environmental, Social, and Governance Reporting
Guide of the Rules Governing the Listing of Securities on The
Stock Exchange of Hong Kong Limited and Guidelines of Shanghai
Stock Exchange of Self-Regulation for Listed Companies No. 1 Standardized Operation. Performance data includes BeiGene’s
owned and operated facilities for the fiscal years 2021 to 2023 unlessotherwise noted. All data are as of December 31, 2023, except where
noted. All monetary figures are in United States Dollars (USD). This
report was reviewed by internal subject matter experts, BeiGene
leadership, and our Board of Directors. Questions or comments about
BeiGene’s Responsible Business & Sustainability performance or thisreport may be submitted to CorporateAffairs@BeiGene.com.

77 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORTOur Approach

AdvancingGlobal Health

Empowering
Our Colleagues

Innovating
Sustainably

OperatingResponsibly

AppendixIntroduction

ForwardLooking
Statement

Our Approach

AdvancingGlobal Health

Empowering
Our Colleagues

and drug candidates, if approved; BeiGene’s ability

in this report does not indicate that such topics

to obtain and maintain protection of intellectual

are material to BeiGene’s business, operations,

property for its medicines and technology;

or financial condition. Website references and

BeiGene’s reliance on third parties to conduct drug

hyperlinks throughout this document are provided

development, manufacturing, commercialization,

for convenience only, and the content on theand other services; BeiGene’s limited experience inreferenced websites is not incorporated into thisobtaining regulatory approvals and commercializing

report. We assume no liability for any third-party

pharmaceutical products and its ability to obtain

content contained on the referenced websites.

Certain statements contained in this report, as welladditional funding for operations and to complete

as websites or materials cross-referenced herein,

the development and commercialization of its drugother than statements of fact that are independently

candidates and achieve and maintain profitability,

verifiable at the date hereof, constitute forward-

as well as those risks more fully discussed in thelooking statements. Examples of such forward-

section entitled “Risk Factors” in BeiGene’s mostlooking statements include statements regarding

recent periodic report filed with the U.S. Securities

our Responsible Business & Sustainability strategy,

and Exchange Commission (SEC), as well as

progress, and goals; BeiGene’s overall growth

discussions of potential risks, uncertainties, andpotential; the potential of, and expectations for, ourother important factors in BeiGene’s subsequentcommercial business and pipeline programs; ourfilings with the SEC. Except where otherwise noted,

future financial and operating results; and BeiGene’s

all information in this presentation is as of the date ofplans, commitments, aspirations, and goals under

this presentation, and BeiGene undertakes no duty

the heading “About BeiGene.” Actual results may

to update such information unless required by law.

differ materially from those indicated in the forwardlooking statements as a result of various important

The inclusion of information contained infactors, including BeiGene’s ability to make progress

this document should not be construed as a

toward and achieve its Responsible Business &characterization regarding the “materiality” of

Sustainability goals; BeiGene’s ability to demonstratethat information in the context of the U.S. federal

the efficacy and safety of its drug candidates; thesecurities laws or any other regulatory framework,

clinical results for its drug candidates, which may noteven where we use words such as “material”

support further development or marketing approval;

or “materiality.” Our approach to Responsible

actions of regulatory agencies, which may affectBusiness & Sustainability disclosures is informed

the initiation, timing, and progress of clinical trials

by impacts on communities, the environment, andand marketing approval; BeiGene’s ability to achieve

stakeholders such as employees, customers, andcommercial success for its marketed medicines

suppliers, and, therefore, the inclusion of topics

78 :: 2023 BEIGENE RESPONSIBLE BUSINESS & SUSTAINABILITY REPORT

Innovating
Sustainably

OperatingResponsibly

Appendix2023 Responsible Business& Sustainability Report